<article title='Antimicrobial_resistance'><paragraph><link><target>File:Antibiotic sensitvity and resistance.JPG</target><part>right</part><part>thumb</part><part>upright=1.4</part><part>Antibiotic resistance tests: Bacteria are streaked on the dish on which antibiotic impregnated white disks are placed. Bacteria in the culture on the left are susceptible to the antibiotic in each disk, as shown by the dark, clear rings where bacteria have not grown. Those on the right are fully susceptible to only three of the seven antibiotics tested.<extension extension_name='ref'><link type='external' href='http://www.microbelibrary.org/component/resource/laboratory-test/3189-kirby-bauer-disk-diffusion-susceptibility-test-protocol'>Kirby-Bauer Disk Diffusion Susceptibility Test Protocol</link>, Jan Hudzicki, ASM</extension></part></link></paragraph><preblock><preline><bold>Antimicrobial resistance</bold><space/>(<bold>AMR</bold>) is when<space/><link><target>microbe</target><trail>s</trail></link><space/>are less treatable with one or more<space/><link><target>antimicrobial</target><part>medications used to treat or prevent</part></link><space/>infection.<extension extension_name='ref' name="WHO2014"><template><target>cite web</target><arg name="title">Antimicrobial resistance Fact sheet N°194</arg><arg name="url">http://www.who.int/mediacentre/factsheets/fs194/en/</arg><arg name="website">who.int</arg><arg name="accessdate">7 March 2015</arg><arg name="date">April 2014</arg></template></extension><space/>There are three main ways by which resistance can occur: natural resistance to certain types of bacteria, genetic mutation, or by acquiring resistance from another bacterium.<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>http://www.tufts.edu/med/apua/about_issue/about_antibioticres.shtml</arg><arg name="url"><space/>http://www.tufts.edu/med/apua/about_issue/about_antibioticres.shtml</arg><arg name="website"><space/>www.tufts.edu</arg><arg name="accessdate"><space/>2015-10-30</arg></template></extension><space/>This phenomenon can happen spontaneously due to mutations of the microbes themselves, to a build up of resistance over time, or to misuse of antibiotics or antimicrobials.<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>About Antimicrobial Resistance</arg><arg><space/>Antibiotic/Antimicrobial Resistance<space/></arg><arg><space/>CDC</arg><arg name="url"><space/>http://www.cdc.gov/drugresistance/about.html</arg><arg name="website"><space/>www.cdc.gov</arg><arg name="accessdate"><space/>2015-10-30</arg></template></extension><space/>Resistant microbes become increasingly difficult to treat, requiring alternative medications or higher doses, both of which may be more costly or more toxic to the individual. Some infections become completely untreatable due to resistance. All classes of microbes develop resistance: fungi<space/><link><target>antifungal</target></link><space/>resistance, viruses<space/><link><target>antiviral</target></link><space/>resistance, protozoans<space/><link><target>antiprotozoal</target></link><space/>resistance, and bacteria<space/><link><target>antibiotic</target></link><space/>resistance. Microbes which are resistant to multiple antimicrobials are termed<space/><italics><link><target>multidrug resistant</target></link></italics><space/>(MDR); in the press, these organisms are often referred to as superbugs.<extension extension_name='ref' name="cdcgetsmart"><template><target>cite web</target><arg name="title">Antibiotic Resistance Questions & Answers</arg><arg name="url">http://www.cdc.gov/getsmart/antibiotic-use/antibiotic-resistance-faqs.html#e</arg><arg name="work">Get Smart: Know When Antibiotics Work</arg><arg name="publisher">Centers for Disease Control and Prevention, USA</arg><arg name="accessdate">20 March 2013</arg><arg name="date">30 June 2009</arg></template></extension><space/>Antimicrobial resistance is an increasingly problematic issue that leads to millions of deaths every year.<extension extension_name='ref' name="WHO 2014"><template><target>cite web</target><arg name="url">http://www.who.int/drugresistance/documents/surveillancereport/en/<space/></arg><arg name="title">Antimicrobial resistance: global report on surveillance 2014<space/></arg><arg name="publisher">WHO<space/></arg><arg name="work">WHO<space/></arg><arg name="date">April 2014<space/></arg><arg name="accessdate">May 9, 2015<space/></arg><arg name="author">WHO</arg></template></extension></preline></preblock><preblock><preline>Antibiotics should only be used when needed and only when prescribed by health professionals.<extension extension_name='ref' name="Swedish"><template><target>Cite book</target><arg name="title"><space/>Swedish work on containment of antibiotic resistance – Tools, methods and experiences</arg><arg name="last"><space/></arg><arg name="first"><space/></arg><arg name="publisher"><space/>Public Health Agency of Sweden</arg><arg name="year"><space/>2014</arg><arg name="isbn"><space/>978-91-7603-011-0</arg><arg name="url"><space/>http://www.folkhalsomyndigheten.se/pagefiles/17351/Swedish-work-on-containment-of-antibiotic-resistance.pdf</arg><arg name="location"><space/>Stockholm</arg><arg name="pages"><space/>16–17, 121–128</arg></template></extension><space/>When antibiotics are being prescribed, the prescriber should closely adhere to the five rights of drug administration: the right patient, the right drug, the right dose, the right route, and the right time.<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>The Five Rights of Medication Administration</arg><arg name="url"><space/>http://www.ihi.org/resources/pages/improvementstories/fiverightsofmedicationadministration.aspx</arg><arg name="website"><space/>www.ihi.org</arg><arg name="accessdate"><space/>2015-10-30</arg></template></extension><space/>Narrow-spectrum antibiotics should be used rather than broad-spectrum antibiotics when possible to effectively and accurately target specific organisms.<extension extension_name='ref' name="NPS2013"><template><target>cite web</target><arg name="title"><space/>Duration of antibiotic therapy and resistance</arg><arg name="url"><space/>http://www.nps.org.au/publications/health-professional/health-news-evidence/2013/duration-of-antibiotic-therapy</arg><arg name="website"><space/>NPS Medicinewise</arg><arg name="accessdate"><space/>22 July 2015</arg><arg name="date"><space/>13 June 2013</arg></template></extension><space/>Cultures should be taken before treatment when indicated and treatment potentially changed based on the susceptibility report.<extension extension_name='ref' name="CDC Mission"><template><target>Cite web</target><arg name="title"><space/>CDC Features – Mission Critical: Preventing Antibiotic Resistance</arg><arg name="url"><space/>http://www.cdc.gov/Features/AntibioticResistance/index.html</arg><arg name="website"><space/>www.cdc.gov</arg><arg name="accessdate"><space/>2015-07-22</arg></template></extension><extension extension_name='ref'><template><target>Cite journal</target><arg name="title"><space/>General Principles of Antimicrobial Therapy</arg><arg name="url"><space/>http://www.mayoclinicproceedings.org/article/S0025-6196(11)60140-7/pdf</arg><arg name="journal"><space/>Mayo Clinic Proceedings</arg><arg name="date"><space/>2011-01-01</arg><arg name="pmc"><space/>3031442</arg><arg name="pmid"><space/>21282489</arg><arg name="volume"><space/>86</arg><arg name="issue"><space/>2</arg><arg name="doi"><space/>10.4065/mcp.2010.0639</arg><arg name="first"><space/>Surbhi</arg><arg name="last"><space/>Leekha</arg><arg name="first2"><space/>Christine L.</arg><arg name="last2"><space/>Terrell</arg><arg name="first3"><space/>Randall S.</arg><arg name="last3"><space/>Edson</arg></template></extension><space/>For people who will be self-administering these medications in the home setting, emphasis must be placed on education about proper use of the drug. In practice, health care providers should try to minimize spread of resistant infections by using proper sanitations techniques including<space/><link><target>handwashing</target></link><space/>or disinfecting between each patient, and should encourage the same of the patient, visitors, and family members.<extension extension_name='ref' name="CDC Mission"></extension><space/></preline></preblock><preblock><preline>The rising trend in drug resistance can be attributed to three primary areas: use of antibiotics in the human population, use of antibiotics in the animal population, and the spread of resistant strains between human or non-human sources.<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>About Antimicrobial Resistance</arg><arg><space/>Antibiotic/Antimicrobial Resistance<space/></arg><arg><space/>CDC</arg><arg name="url"><space/>http://www.cdc.gov/drugresistance/about.html</arg><arg name="website"><space/>www.cdc.gov</arg><arg name="accessdate"><space/>2015-10-30</arg></template></extension><space/>Any use of antibiotics can increase<space/><link><target>selective pressure</target></link><space/>in a population of bacteria, causing vulnerable bacteria to die thereby increasing the relative numbers of resistant bacteria and allowing for further growth. As resistance to antibiotics becomes more common there is greater need for alternative treatments. Call for new antibiotic therapies have been issued, but there is continuing decline in the number of approved drugs.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Cassir</arg><arg name="first1">N</arg><arg name="last2">Rolain</arg><arg name="first2">JM</arg><arg name="last3">Brouqui</arg><arg name="first3">P</arg><arg name="title">A new strategy to fight antimicrobial resistance: the revival of old antibiotics.</arg><arg name="journal">Frontiers in microbiology</arg><arg name="date">2014</arg><arg name="volume">5</arg><arg name="pages">551</arg><arg name="pmid">25368610</arg><arg name="doi">10.3389/fmicb.2014.00551</arg></template></extension><space/>The Centers for Disease Control and Prevention (CDC) has developed a monitoring program for the top 18 drug-resistant threats in the United States, categorized by level of concern; examples of common types of drug-resistant bacteria include:<space/><link><target>methicillin-resistant Staphylococcus aureus</target><part>methicillin-resistant ''Staphylococcus aureus''</part></link><space/>(MRSA),<space/><link><target>Vancomycin-resistant Staphylococcus aureus</target><part>vancomycin-resistant ''S. aureus''</part></link><space/>(VRSA),<space/><link><target>Beta-lactamase</target><part>extended spectrum beta-lactamase</part></link><space/>(ESBL),<space/><link><target>Vancomycin-resistant Enterococcus</target><part>vancomycin-resistant ''Enterococcus''</part></link><space/>(VRE),<space/><link><target>Acinetobacter baumannii</target><part>multidrug-resistant ''A. baumannii''</part></link><space/>(MRAB).</preline></preblock><preblock><preline>A<space/><link><target>World Health Organization</target></link><space/>(WHO) report released April 2014 stated, &quot;this serious threat is no longer a prediction for the future, it is happening right now in every region of the world and has the potential to affect anyone, of any age, in any country. Antibiotic resistancewhen bacteria change so antibiotics no longer work in people who need them to treat infectionsis now a major threat to public health.&quot;<extension extension_name='ref' name="who.int"><link type='external' href='http://www.who.int/mediacentre/news/releases/2014/amr-report/en/'>&quot;WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health&quot;</link><space/>Retrieved 2014-05-02</extension><space/>There have been increasing public calls for global collective action to address the threat, including a proposal for an<space/><link><target>international treaty</target></link><space/>on antimicrobial resistance.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Hoffman</arg><arg name="first1">SJ</arg><arg name="last2">Outterson</arg><arg name="first2">K</arg><arg name="last3">Røttingen</arg><arg name="first3">JA</arg><arg name="last4">Cars</arg><arg name="first4">O</arg><arg name="last5">Clift</arg><arg name="first5">C</arg><arg name="last6">Rizvi</arg><arg name="first6">Z</arg><arg name="last7">Rotberg</arg><arg name="first7">F</arg><arg name="last8">Tomson</arg><arg name="first8">G</arg><arg name="last9">Zorzet</arg><arg name="first9">A</arg><arg name="title">An international legal framework to address antimicrobial resistance</arg><arg name="journal">Bulletin of the World Health Organization</arg><arg name="date">February 2015</arg><arg name="volume">93</arg><arg name="issue">2</arg><arg name="page">66</arg><arg name="doi">10.2471/BLT.15.152710</arg><arg name="pmid">25883395</arg><arg name="url">http://www.who.int/bulletin/volumes/93/2/15-152710.pdf</arg><arg name="accessdate">8 July 2015</arg></template></extension><space/>Antibiotic resistance is not properly mapped across the world, but the countries that are affected the most are poorer countries with already weaker healthcare systems.<extension extension_name='ref' name="Swedish"></extension></preline></preblock><paragraph><template><target>TOC limit</target><arg>3</arg></template></paragraph><heading level='2'>Definition</heading><paragraph><link><target>File:WhatIsDrugResistance.gif</target><part>thumb</part><part>300x300px</part><part>Diagram showing the difference between non-resistant bacteria and drug resistant bacteria. Non-resistant bacteria multiply, and upon drug treatment, the bacteria die. Drug resistant bacteria multiply as well, but upon drug treatment, the bacteria continue to spread.<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>What is Drug Resistance?</arg><arg name="url"><space/>http://www.niaid.nih.gov/topics/antimicrobialResistance/Understanding/Pages/drugResistanceDefinition.aspx</arg><arg name="website"><space/>www.niaid.nih.gov</arg><arg name="accessdate"><space/>2015-07-26</arg></template></extension></part></link>The WHO defines antimicrobial resistance as a microorganism's resistance to an antimicrobial drug that was once able to treat an infection by that microorganism.<extension extension_name='ref' name="WHO2014"></extension>A person cannot become resistant to antibiotics. Resistance is a property of the microbe, not the person or other organism infected by the microbe.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.cdc.gov/getsmart/antibiotic-use/antibiotic-resistance-faqs.html#antibiotic-resistance-concerns</arg><arg name="title">CDC: Get Smart: Know When Antibiotics Work<space/></arg><arg name="publisher">Cdc.gov<space/></arg><arg name="accessdate">2013-06-12</arg></template></extension></paragraph><heading level='2'>Causes</heading><paragraph><link><target>File:CDCinfographicANTIBIORESISTANCE.png</target><part>thumb</part><part>How antibiotic resistance evolves and spreads</part><part>390x390px</part></link>Some bacteria with resistance to antibiotics predate the medical use of antibiotics by humans;<extension extension_name='ref'><template><target>Cite journal</target><arg name="journal"><space/>Nature<space/></arg><arg name="date"><space/>2011<space/></arg><arg name="volume"><space/>477<space/></arg><arg name="issue"><space/>7365<space/></arg><arg name="pages"><space/>457–461<space/></arg><arg name="doi"><space/>10.1038/nature10388<space/></arg><arg name="title"><space/>Antibiotic resistance is ancient<space/></arg><arg name="author"><space/>D'Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, Froese D, Zazula G, Calmels F, Debruyne R, Golding GB, Poinar HN, Wright GD</arg><arg name="bibcode"><space/>2011Natur.477..457D<space/></arg></template></extension><template><target>sfn</target><arg>Caldwell</arg><arg>Lindberg</arg><arg>2011</arg></template><template><target>sfn</target><arg>Nelson</arg><arg>2009</arg><arg name="p">294</arg></template><space/>however, widespread antibiotic use has caused more bacteria to become resistant, a process called<space/><link><target>evolutionary pressure</target></link>.<template><target>sfn</target><arg>Hawkey</arg><arg>Jones</arg><arg>2009</arg><arg name="pp">i3-i10</arg></template><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Goossens H, Ferech M, Vander Stichele R, Elseviers M<space/></arg><arg name="title">Outpatient antibiotic use in Europe and association with resistance: a cross-national database study<space/></arg><arg name="journal">Lancet<space/></arg><arg name="volume">365<space/></arg><arg name="issue">9459<space/></arg><arg name="pages">579–87<space/></arg><arg name="year">2005<space/></arg><arg name="pmid">15708101<space/></arg><arg name="doi">10.1016/S0140-6736(05)17907-0<space/></arg><arg name="url"></arg></template><template><target>subscription required</target></template></extension></paragraph><paragraph>Reasons for the widespread use of antibiotics include:</paragraph><list type='bullet'><listitem>increasing global availability over time since the 1950s</listitem><listitem>uncontrolled sale in many low or middle income countries, where they can be obtained over the counter without a prescription, potentially resulting in antibiotics being used when not indicated.<extension extension_name='ref' name="lid13">The Lancet Infectious Diseases Commission.<space/><link type='external' href='http://www.princeton.edu/pei/news/S1473309913703189-main.pdf'>Antibiotic resistancethe need for global solutions.</link><space/>Lancet Infect Dis 2013;13: 105798.</extension><template><target>rp</target><arg>1060</arg></template><space/>This may result in emergence of resistance in any remaining bacteria.</listitem></list><paragraph><link><target>Antibiotic use in livestock</target></link><space/>feed at low doses for growth promotion is an accepted practice in many industrialized countries which leads to resistance.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ferber D<space/></arg><arg name="title"><space/>Livestock Feed Ban Preserves Drugs' Power<space/></arg><arg name="journal"><space/>Science<space/></arg><arg name="volume"><space/>295<space/></arg><arg name="issue"><space/>5552<space/></arg><arg name="pages"><space/>27–28<space/></arg><arg name="date"><space/>4 January 2002<space/></arg><arg name="pmid"><space/>11778017<space/></arg><arg name="doi"><space/>10.1126/science.295.5552.27a<space/></arg><arg name="ref"><space/>harv<space/></arg></template><template><target>subscription required</target></template></extension><extension extension_name='ref' name="mathew"></extension><space/>Releasing large quantities of antibiotics into the environment during pharmaceutical manufacturing by inadequate treatment of wastewater contributes to the likelihood of creating antibiotic-resistant strains.<extension extension_name='ref'><template><target>cite news</target><arg name="title">Pharmaceuticals Sold In Sweden Cause Serious Environmental Harm In India, Research Shows</arg><arg name="url">http://www.sciencedaily.com/releases/2009/02/090205083522.htm</arg><arg name="accessdate">29 January 2015</arg><arg name="work">ScienceDaily</arg><arg name="publisher">ScienceDaily, LLC</arg><arg name="date">7 February 2009</arg><arg name="quote">We estimated that the[water] treatment plant released 45 kilograms of the antibiotic ciprofloxacin in one day, which is equivalent to five times the daily consumption of Sweden,”</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Larsson DG, Fick J<space/></arg><arg name="title"><space/>Transparency throughout the production chain – a way to reduce pollution from the manufacturing of pharmaceuticals?<space/></arg><arg name="journal"><space/>[[Regul Toxicol Pharmacol]]<space/></arg><arg name="volume"><space/>53<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>161–3<space/></arg><arg name="date"><space/>Jan 2009<space/></arg><arg name="pmid"><space/>19545507<space/></arg><arg name="doi"><space/>10.1016/j.yrtph.2009.01.008<space/></arg><arg name="ref"><space/>harv<space/></arg></template><template><target>subscription required</target></template></extension><space/>It is uncertain whether antibacterials in soaps and other products contribute to antibiotic resistance, but they are discouraged for other reasons.<extension extension_name='ref'><template><target>cite web</target><arg name="last">CDC</arg><arg name="url">http://www.cdc.gov/getsmart/antibiotic-use/antibiotic-resistance-faqs.html#antibacterial-products<space/></arg><arg name="trans_title"><space/>Are antibacterial-containing products (soaps, household cleaners, etc.) better for preventing the spread of infection? Does their use add to the problem of resistance?</arg><arg name="title">Antibiotic Resistance Questions and Answers<space/></arg><arg name="publisher">Centers for Disease Control and Prevention</arg><arg name="location">Atlanta, Georgia, USA.<space/></arg><arg name="accessdate"><space/>February 25, 2015</arg><arg name="ref">harv</arg><arg name="deadurl"><space/>no</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Allison E. Aiello, Elaine L. Larson, Stuart B. Levy<space/></arg><arg name="title"><space/>Consumer Antibacterial Soaps: Effective or Just Risky?<space/></arg><arg name="journal"><space/>[[Clinical Infectious Diseases]]<space/></arg><arg name="volume"><space/>45<space/></arg><arg name="issue"><space/>Supplement 2<space/></arg><arg name="pages"><space/>S137-47</arg><arg name="date"><space/>2007<space/></arg><arg name="doi"><space/>10.1086/519255<space/></arg><arg name="pmid">17683018</arg></template></extension></paragraph><heading level='3'>Human medicine</heading><paragraph><link><target>File:AntimcrresUKreview2.jpg</target><part>thumb</part><part>Deaths attributable to antimicrobial resistance every year compared to other major causes of death.</part><part>300x300px</part></link>Increasing bacterial resistance is linked with the volume of antibiotic prescribed, as well as missing doses when taking antibiotics.<extension extension_name='ref' name="Pechre JC 2001 S1703"><template><target>cite journal</target><arg name="author">Pechère JC<space/></arg><arg name="title">Patients' interviews and misuse of antibiotics<space/></arg><arg name="journal">Clin. Infect. Dis.<space/></arg><arg name="volume">33 Suppl 3<space/></arg><arg name="pages">S170–3<space/></arg><arg name="date">September 2001<space/></arg><arg name="pmid">11524715<space/></arg><arg name="doi">10.1086/321844</arg><arg name="quote"><space/>Noncompliance may have an impact on antibiotic resistance... Type A consists in shorter than prescribed courses. By reducing the antibiotic pressure, provided that the daily doses are otherwise respected, one may see a theoretical advantage... Type B noncompliance reduces the number of daily doses... indicate that such underdosing may promote the selection of resistance</arg></template></extension><space/>Inappropriate prescribing of antibiotics has been attributed to a number of causes, including people insisting on antibiotics, physicians prescribing them as they feel they do not have time to explain why they are not necessary, and physicians not knowing when to prescribe antibiotics or being overly cautious for medical and/or legal reasons.<extension extension_name='ref' name="Arn2005"><template><target>cite journal</target><arg name="author"><space/>Arnold SR, Straus SE<space/></arg><arg name="title"><space/>Interventions to improve antibiotic prescribing practices in ambulatory care<space/></arg><arg name="journal"><space/>Cochrane Database of Systematic Reviews<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>CD003539<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>16235325<space/></arg><arg name="doi"><space/>10.1002/14651858.CD003539.pub2<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="editor1-last"><space/>Arnold<space/></arg><arg name="editor1-first"><space/>Sandra R<space/></arg><arg name="last2"><space/>Straus<space/></arg><arg name="first2"><space/>SE<space/></arg></template></extension></paragraph><paragraph>Increasing bacterial resistance is linked with the volume of antibiotic prescribed, as well as missing doses when taking antibiotics.<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>http://www.tufts.edu/med/apua/about_issue/what_can_be_done.shtml</arg><arg name="url"><space/>http://www.tufts.edu/med/apua/about_issue/what_can_be_done.shtml</arg><arg name="website"><space/>www.tufts.edu</arg><arg name="accessdate"><space/>2015-10-30</arg></template></extension><space/>Up to half of antibiotics used in humans are unnecessary and inappropriate.<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>About Antimicrobial Resistance</arg><arg><space/>Antibiotic/Antimicrobial Resistance<space/></arg><arg><space/>CDC</arg><arg name="url"><space/>http://www.cdc.gov/drugresistance/about.html</arg><arg name="website"><space/>www.cdc.gov</arg><arg name="accessdate"><space/>2015-10-30</arg></template></extension><space/>For example, a third of people believe that antibiotics are effective for the<space/><link><target>common cold</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>McNulty CA, Boyle P, Nichols T, Clappison P, Davey P<space/></arg><arg name="title"><space/>The public's attitudes to and compliance with antibiotics<space/></arg><arg name="journal"><space/>[[J. Antimicrob. Chemother.]]<space/></arg><arg name="volume"><space/>60 Suppl 1<space/></arg><arg name="pages"><space/>i63–8<space/></arg><arg name="date"><space/>August 2007<space/></arg><arg name="pmid"><space/>17656386<space/></arg><arg name="doi"><space/>10.1093/jac/dkm161<space/></arg><arg name="ref"><space/>harv<space/></arg></template><template><target>subscription required</target></template></extension><space/>and the common cold is the most common reason antibiotics are prescribed<extension extension_name='ref'><template><target>cite book</target><arg name="last">editors</arg><arg name="first">Ronald Eccles, Olaf Weber,<space/></arg><arg name="title">Common cold</arg><arg name="year">2009</arg><arg name="publisher">Birkhäuser</arg><arg name="location">Basel</arg><arg name="isbn">978-3-7643-9894-1</arg><arg name="url">http://books.google.ca/books?id</arg><arg name="edition">Online-Ausg.</arg><arg name="page"><space/>234</arg></template></extension><space/>even though antibiotics are useless against viruses. A single regimen of antibiotics even in compliant individuals leads to a greater risk of resistant organisms to that antibiotic in the person for a month to possibly a year.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD<space/></arg><arg name="title"><space/>Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis<space/></arg><arg name="journal"><space/>[[British Medical Journal]]<space/></arg><arg name="volume"><space/>340<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>c2096<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>20483949<space/></arg><arg name="doi"><space/>10.1136/bmj.c2096<space/></arg></template><template><target>subscription required</target></template></extension><extension extension_name='ref'><template><target>cite book</target><arg name="title">Antimicrobial Resistance: Tackling a Crises for the Health and Welfare of Nations: 2014</arg><arg name="date">11 December 2014</arg><arg name="publisher">Jim O'Neill Gibbs Building, 215 Euston Road, London, NW1 2BE</arg><arg></arg></template><template><target>subscription required</target></template></extension></paragraph><paragraph>Antibiotic resistance increases with duration of treatment; therefore, as long as an effective minimum is kept, shorter courses of antibiotics are likely to decrease rates of resistance, reduce cost, and have better outcomes due to fewer complications.<extension extension_name='ref' name="NPS2013"></extension><space/>Short course regimens exist for<space/><link><target>community-acquired pneumonia</target></link><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Li JZ, Winston LG, Moore DH, Bent S<space/></arg><arg name="title"><space/>Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis<space/></arg><arg name="journal"><space/>Am. J. Med.<space/></arg><arg name="volume"><space/>120<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>783–90<space/></arg><arg name="date"><space/>September 2007<space/></arg><arg name="pmid"><space/>17765048<space/></arg><arg name="doi"><space/>10.1016/j.amjmed.2007.04.023<space/></arg><arg name="ref"><space/>harv<space/></arg></template><template><target>subscription required</target></template></extension><space/><link><target>spontaneous bacterial peritonitis</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA<space/></arg><arg name="title"><space/>Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients<space/></arg><arg name="journal"><space/>Gastroenterology<space/></arg><arg name="volume"><space/>100<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>1737–42<space/></arg><arg name="date"><space/>June 1991<space/></arg><arg name="pmid"><space/>2019378<space/></arg></template><template><target>subscription required</target></template></extension><space/>suspected lung infections in ICU patients,<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL<space/></arg><arg name="title"><space/>Short-course Empiric Antibiotic Therapy for Patients with Pulmonary Infiltrates in the Intensive Care Unit A Proposed Solution for Indiscriminate Antibiotic Prescription<space/></arg><arg name="journal"><space/>Am. J. Respir. Crit. Care Med.<space/></arg><arg name="volume"><space/>162<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>505–511<space/></arg><arg name="date"><space/>1 August 2000<space/></arg><arg name="pmid"><space/>10934078<space/></arg><arg name="doi"><space/>10.1164/ajrccm.162.2.9909095<space/></arg></template><template><target>subscription required</target></template></extension><space/>in the so-called<space/><link><target>acute abdomen</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Gleisner AL, Argenta R, Pimentel M, Simon TK, Jungblut CF, Petteffi L, de Souza RM, Sauerssig M, Kruel CD, Machado AR<space/></arg><arg name="title"><space/>Infective complications according to duration of antibiotic treatment in acute abdomen<space/></arg><arg name="journal"><space/>International Journal of Infectious Diseases<space/></arg><arg name="volume"><space/>8<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>155–162<space/></arg><arg name="date"><space/>30 April 2004<space/></arg><arg name="pmid"><space/>15109590<space/></arg><arg name="doi"><space/>10.1016/j.ijid.2003.06.003<space/></arg></template><template><target>subscription required</target></template></extension><space/>middle ear infection, sinusitis and throat infection,<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Pichichero ME, Cohen R<space/></arg><arg name="title"><space/>Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis<space/></arg><arg name="journal"><space/>The Pediatric Infectious Disease Journal<space/></arg><arg name="volume"><space/>16<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>680–95<space/></arg><arg name="year"><space/>1997<space/></arg><arg name="pmid"><space/>9239773<space/></arg><arg name="doi"><space/>10.1097/00006454-199707000-00011<space/></arg></template><template><target>subscription required</target></template></extension><space/>and penetrating gut injury.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Dellinger EP, Wertz MJ, Lennard ES, Oreskovich MR<space/></arg><arg name="title"><space/>Efficacy of Short-Course Antibiotic Prophylaxis After Penetrating Intestinal Injury<space/></arg><arg name="journal"><space/>Archives of Surgery<space/></arg><arg name="volume"><space/>121<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>23–30<space/></arg><arg name="year"><space/>1986<space/></arg><arg name="pmid"><space/>3942496<space/></arg><arg name="doi"><space/>10.1001/archsurg.1986.01400010029002<space/></arg></template><template><target>subscription required</target></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Perez-Gorricho B, Ripoll M<space/></arg><arg name="title"><space/>Does short-course antibiotic therapy better meet patient expectations?<space/></arg><arg name="journal"><space/>International Journal of Antimicrobial Agents<space/></arg><arg name="volume"><space/>21<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>222–8<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>12636982<space/></arg><arg name="doi"><space/>10.1016/S0924-8579(02)00360-6<space/></arg></template><template><target>subscription required</target></template></extension><space/>In some situations a short course may not cure the infection as well as a long course.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Keren R, Chan E<space/></arg><arg name="title"><space/>A Meta-analysis of Randomized, Controlled Trials Comparing Short- and Long-Course Antibiotic Therapy for Urinary Tract Infections in Children<space/></arg><arg name="journal"><space/>Pediatrics<space/></arg><arg name="volume"><space/>109<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>E70–0<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="pmid"><space/>11986476<space/></arg><arg name="doi"><space/>10.1542/peds.109.5.e70<space/></arg></template><template><target>subscription required</target></template></extension><space/>A<space/><link><target>BMJ</target></link><space/>editorial recommended that antibiotics can often be safely stopped 72&amp;nbsp;hours after symptoms resolve.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>McCormack J, Allan GM<space/></arg><arg name="title"><space/>A prescription for improving antibiotic prescribing in primary care<space/></arg><arg name="journal"><space/>[[British Medical Journal]]<space/></arg><arg name="volume"><space/>344<space/></arg><arg name="pages"><space/>d7955<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22302779<space/></arg><arg name="doi"><space/>10.1136/bmj.d7955<space/></arg></template><template><target>subscription required</target></template></extension><space/>Because individuals may feel better before the infection is eradicated, doctors must provide instructions to them so they know when it is safe to stop taking a prescription. Some researchers advocate doctors' using a very short course of antibiotics, reevaluating the patient after a few days, and stopping treatment if there are no clinical signs of infection.<extension extension_name='ref'>Marc Bonten, MD; Eijkman-Winkler Institute for Medical Microbiology, Utrecht, the Netherland |<space/><link type='external' href='http://hicsigwiki.asid.net.au/images/4/41/Should_you_stop_an_antibiotic_course_early_if_you_feel_better_R._Everts.pdf'>Infectious Diseases, and Inflammation</link></extension></paragraph><paragraph>Certain<space/><link><target>antibiotic classes</target></link><space/>result in resistance more than others. Increased rates of MRSA infections are seen when using<space/><link><target>glycopeptides</target></link>,<space/><link><target>cephalosporin</target><trail>s</trail></link>, and<space/><link><target>quinolones</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R<space/></arg><arg name="title"><space/>Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis<space/></arg><arg name="journal"><space/>J. Antimicrob. Chemother.<space/></arg><arg name="volume"><space/>61<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>26–38<space/></arg><arg name="date"><space/>January 2008<space/></arg><arg name="pmid"><space/>17986491<space/></arg><arg name="doi"><space/>10.1093/jac/dkm416<space/></arg><arg name="ref"><space/>harv<space/></arg></template><template><target>subscription required</target></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, Farr BM<space/></arg><arg name="title"><space/>SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus<space/></arg><arg name="journal"><space/>Infect Control Hosp Epidemiol<space/></arg><arg name="volume"><space/>24<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>362–86<space/></arg><arg name="date"><space/>May 2003<space/></arg><arg name="pmid"><space/>12785411<space/></arg><arg name="doi"><space/>10.1086/502213<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension><space/>Cephalosporins, and particularly quinolones and<space/><link><target>clindamycin</target></link>, are more likely to produce colonisation with<space/><italics><link><target>Clostridium difficile</target></link></italics><template><target>importance-inline</target></template><extension extension_name='ref'><template><target>cite web</target><arg name="first">Dr Ralf-Peter<space/></arg><arg name="last">Vonberg<space/></arg><arg name="title">Clostridium difficile: a challenge for hospitals<space/></arg><arg name="url">http://www.ihe-online.com/feature-articles/clostridium-difficile-a-challenge-for-hospitals/trackback/1/index.html<space/></arg><arg name="work">European Center for Disease Prevention and Control<space/></arg><arg name="publisher">IHE<space/></arg><arg name="location">Institute for Medical Microbiology and Hospital Epidemiology<space/></arg><arg name="accessdate">27 July 2009</arg><arg name="ref">harv</arg><arg name="archiveurl"><space/>http://web.archive.org/web/20090611151535/http://www.ihe-online.com/feature-articles/clostridium-difficile-a-challenge-for-hospitals/trackback/1/index.html</arg><arg name="archivedate"><space/>11 June 2009</arg><arg name="deadurl"><space/>no</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Kuijper EJ, van Dissel JT, Wilcox MH<space/></arg><arg name="title"><space/>Clostridium difficile: changing epidemiology and new treatment options<space/></arg><arg name="journal"><space/>Current Opinion in Infectious Diseases<space/></arg><arg name="volume"><space/>20<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>376–83<space/></arg><arg name="date"><space/>Aug 2007<space/></arg><arg name="pmid"><space/>17609596<space/></arg><arg name="doi"><space/>10.1097/QCO.0b013e32818be71d<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="last3"><space/>Wilcox<space/></arg><arg name="last2"><space/>van Dissel<space/></arg><arg name="first2"><space/>J.<space/></arg><arg name="first3"><space/>MH<space/></arg><arg name="subscription">yes</arg></template></extension></paragraph><paragraph>Factors within the intensive care unit setting such as mechanical ventilation and multiple underlying diseases also appear to contribute to bacterial resistance.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ<space/></arg><arg name="title"><space/>Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy<space/></arg><arg name="journal"><space/>Antimicrob. Agents Chemother.<space/></arg><arg name="volume"><space/>42<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>521–7<space/></arg><arg name="date"><space/>March 1998<space/></arg><arg name="pmid"><space/>9517926<space/></arg><arg name="pmc"><space/>105492<space/></arg><arg name="ref"><space/>harv<space/></arg></template><template><target>subscription required</target></template></extension><space/>Poor hand hygiene by hospital staff has been associated with the spread of resistant organisms,<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Girou E, Legrand P, Soing-Altrach S, Lemire A, Poulain C, Allaire A, Tkoub-Scheirlinck L, Chai SH, Dupeyron C, Loche CM<space/></arg><arg name="title"><space/>Association between hand hygiene compliance and methicillin-resistant Staphylococcus aureus prevalence in a French rehabilitation hospital<space/></arg><arg name="journal"><space/>Infect Control Hosp Epidemiol<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>1128–30<space/></arg><arg name="date"><space/>October 2006<space/></arg><arg name="pmid"><space/>17006822<space/></arg><arg name="doi"><space/>10.1086/507967<space/></arg><arg name="ref"><space/>harv<space/></arg></template><template><target>subscription required</target></template></extension><space/>and an increase in hand washing compliance results in decreased rates of these organisms.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Swoboda SM, Earsing K, Strauss K, Lane S, Lipsett PA<space/></arg><arg name="title"><space/>Electronic monitoring and voice prompts improve hand hygiene and decrease nosocomial infections in an intermediate care unit<space/></arg><arg name="journal"><space/>Crit. Care Med.<space/></arg><arg name="volume"><space/>32<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>358–63<space/></arg><arg name="date"><space/>February 2004<space/></arg><arg name="pmid"><space/>14758148<space/></arg><arg name="doi"><space/>10.1097/01.CCM.0000108866.48795.0F<space/></arg><arg name="ref"><space/>harv<space/></arg></template><template><target>subscription required</target></template></extension></paragraph><paragraph>The improper use of antibiotics can often be attributed to the presence of<space/><link><target>structural violence</target></link><space/>in particular regions. Socioeconomic factors such as race and poverty affect accessibility of and adherence to drug therapy. The efficacy of treatment programs for drug-resistant strains depends on whether or not programmatic improvements take into account the effects of structural violence.<extension extension_name='ref'>Farmer, Paul E., Bruce Nizeye, Sara Stulac, and Salmaan Keshavjee. 2006. Structural Violence and Clinical Medicine. PLoS Medicine, 16861691. url=?</extension></paragraph><heading level='3'>Veterinary medicine</heading><paragraph><template><target>main</target><arg>Antibiotic use in livestock</arg></template><link><target>File:Ar-infographic-950px.jpg</target><part>thumb</part><part>300px</part><part>All animals carry bacteria in their intestines. Antibiotics are given to animals. Antibiotics kill most bacteria. But resistant bacteria survive and multiply.</part></link>Eighty percent of antibiotics sold in the United States are used on livestock. The majority of these antibiotics are given to animals that are otherwise health. Rather, it is normal practice to mix antibiotics with livestock food to promote healthier living conditions and to encourage animal growth.<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>Antibiotic Resistance {{!}} NRDC</arg><arg name="url"><space/>http://www.nrdc.org/food/saving-antibiotics.asp</arg><arg name="website"><space/>www.nrdc.org</arg><arg name="accessdate"><space/>2015-10-30</arg></template></extension><space/>The use of antibiotics in animals is to a large degree involved in the emergence of antibiotic-resistant microorganisms.<extension extension_name='ref'><link type='external' href='http://www.ncbi.nlm.nih.gov/books/NBK97126/'>The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary</link>. Institute of Medicine (US) Forum on Emerging Infections; Knobler SL, Lemon SM, Najafi M, et al., editors. Washington (DC): National Academies Press (US); 2003.</extension><space/>Antibiotics are used in food with the intention of not only preventing, controlling, and treating diseases, but also to promote growth.<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>About Antimicrobial Resistance</arg><arg><space/>Antibiotic/Antimicrobial Resistance<space/></arg><arg><space/>CDC</arg><arg name="url"><space/>http://www.cdc.gov/drugresistance/about.html</arg><arg name="website"><space/>www.cdc.gov</arg><arg name="accessdate"><space/>2015-10-30</arg></template></extension><space/>Antibiotic use in animals can be classified into therapeutic, prophylactic, metaphylactic, and growth promotion uses of antibiotics.<extension extension_name='ref'><template><target>Wayback</target><arg name="url">http://www.who.int/foodsafety/publications/micro/en/amr.pdf</arg><arg name="title">Joint FAO/OIE/WHO Expert Workshop on Non-Human Antimicrobial Usage and Antimicrobial Resistance: Scientific assessment</arg><arg name="date">20040926123121</arg><arg name="df">yes</arg></template></extension><space/>All four patterns select for bacterial resistance, since antibiotic resistance is a natural evolutionary process, but the non-therapeutic uses expose larger number of animals, and therefore of bacteria, for more extended periods, and at lower doses. They therefore greatly increase the cross-section for the evolution of resistance.</paragraph><paragraph><link><target>File:TangledwebSaureus.png</target><part>thumb</part><part>The origins of antibiotic-resistant ''Staphylococcus aureus'' (CAFO: concentrated animal feeding operations)</part><part>313x313px</part></link><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Smith</arg><arg name="first1">TC</arg><arg name="title">Livestock-Associated Staphylococcus aureus: The United States Experience.</arg><arg name="journal">PLOS Pathogens</arg><arg name="date">February 2015</arg><arg name="volume">11</arg><arg name="issue">2</arg><arg name="pages">e1004564</arg><arg name="pmid">25654425</arg><arg name="doi">10.1371/journal.ppat.1004564</arg></template></extension><space/>Since the last third of the 20th century, antibiotics have been used extensively in<space/><link><target>animal husbandry</target></link>. In 2013, 80% of antibiotics used in the US were used in animals and only 20% in humans; in 1997 half were used in humans and half in animals.<extension extension_name='ref' name="TheRealNews-2014-05-18"><template><target>cite web</target><arg name="url">http://therealnews.com/t2/index.php?option</arg><arg name="title">Why Are Antibiotics Becoming Useless All Over the World?<space/></arg><arg name="author">[[Martin Khor]]</arg><arg name="date">2014-05-18</arg><arg name="publisher">''[[The Real News]]''</arg><arg name="accessdate">2014-05-18</arg></template></extension><space/>Some antibiotics are not used and not considered significant for use in humans, because they either lack efficacy or purpose in humans, such as<space/><link><target>ionophore</target><trail>s</trail></link><space/>in ruminants,<extension extension_name='ref'><template><target>cite web</target><arg name="last">Hersom</arg><arg name="first">Matt</arg><arg name="title">Application of Ionophores in Cattle Diets</arg><arg name="url">http://edis.ifas.ufl.edu/pdffiles/AN/AN28500.pdf</arg><arg name="work">AN285 Department of Animal Sciences</arg><arg name="publisher">University of Florida IFAS Extension</arg><arg name="accessdate">14 March 2013</arg></template></extension><space/>or because the drug has gone out of use in humans. Others are used in both animals and humans, including penicillin and some forms of tetracycline.<extension extension_name='ref'>The Editorial Board of the<space/><italics><link><target>New York Times</target></link></italics>, May 10, 2014,<space/><link type='external' href='http://www.nytimes.com/2014/05/11/opinion/sunday/the-rise-of-antibiotic-resistance.html?ref=opinion&amp;amp;_r=0'>The Rise of Antibiotic Resistance</link></extension><space/>Historically, regulation of antibiotic use in food animals has been limited to limiting drug residues in meat, egg, and milk products, rather than by direct concern over the development of antibiotic resistance. This mirrors the primary concerns in human medicine, where, in general, researchers and doctors were more concerned about effective but non-toxic doses of drugs rather than antibiotic resistance.</paragraph><paragraph>In 2001, the<space/><link><target>Union of Concerned Scientists</target></link><space/>estimated that greater than 70% of the antibiotics used in the U.S. are given to food animals (for example, chickens, pigs, and cattle), in the absence of disease.<extension extension_name='ref' name="TheRealNews-2014-05-18"></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.ucsusa.org/food_and_environment/antibiotics_and_food/hogging-it-estimates-of-antimicrobial-abuse-in-livestock.html</arg><arg name="title"><space/>Executive summary from the UCS report "Hogging It: Estimates of Antimicrobial Abuse in Livestock"</arg><arg name="publisher">Union of Concerned Scientists</arg><arg name="date">January 2001</arg><arg name="ref">harv</arg></template></extension><space/>The amounts given are termed &quot;sub-therapeutic&quot;, i.e., insufficient to combat disease. Despite no diagnosis of disease, the administration of these drugs (most of which are not significant to human medicine) results in decreased mortality and morbidity and increased growth in the animals so treated. It is theorized that sub-therapeutic dosages kills some, but not all, of the bacterial organisms in the animal likely leaving those that are naturally antibiotic-resistant.<extension extension_name='ref'><link type='external' href='http://www.ncbi.nlm.nih.gov/books/NBK114485/'>Antibiotic Resistance - Linking Human And Animal Health: Improving Food Safety Through a One Health Approach Workshop Summary</link>. Wegener, Henrik C. Washington (DC): National Academies Press (US); 2012.</extension><space/>Studies have shown, however, that, in essence, the overall population levels of bacteria are unchanged; only the mix of bacteria is affected.<template><target>citation needed</target><arg name="date">May 2012</arg></template><space/>The actual mechanism by which sub-therapeutic antibiotic feed additives serve as growth promoters is thus unclear. Some people have speculated that animals and fowl may have sub-clinical infections, which would be cured by low levels of antibiotics in feed, thereby allowing the creatures to thrive. No convincing evidence has been advanced for this theory, and the bacterial load in an animal is essentially unchanged by use of antibiotic feed additives. The mechanism of growth promotion is therefore probably something other than &quot;killing off the bad bugs.&quot;</paragraph><paragraph>Antibiotics are used in U.S. animal feed to promote animal productivity.<extension extension_name='ref' name="mathew"><template><target>cite journal</target><arg name="author"><space/>Mathew AG, Cissell R, Liamthong S<space/></arg><arg name="title"><space/>Antibiotic resistance in bacteria associated with food animals: a United States perspective of livestock production<space/></arg><arg name="journal"><space/>Foodborne Pathog. Dis.<space/></arg><arg name="volume"><space/>4<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>115–33<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17600481<space/></arg><arg name="doi"><space/>10.1089/fpd.2006.0066<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="last3"><space/>Liamthong<space/></arg><arg name="last2"><space/>Cissell<space/></arg><arg name="first2"><space/>R<space/></arg><arg name="first3"><space/>S<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Sapkota AR, Lefferts LY, McKenzie S, Walker P<space/></arg><arg name="title"><space/>What Do We Feed to Food-Production Animals? A Review of Animal Feed Ingredients and Their Potential Impacts on Human Health<space/></arg><arg name="journal"><space/>Environ. Health Perspect.<space/></arg><arg name="volume"><space/>115<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>663–70<space/></arg><arg name="date"><space/>May 2007<space/></arg><arg name="pmid"><space/>17520050<space/></arg><arg name="pmc"><space/>1867957<space/></arg><arg name="doi"><space/>10.1289/ehp.9760<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension><space/>In particular, poultry feed and water is a common route of administration of drugs, due to higher overall costs when drugs are administered by handling animals individually.</paragraph><paragraph>In research studies, occasional animal-to-human spread of drug-resistant organisms has been demonstrated. Resistant bacteria can be transmitted from animals to humans in three ways: by consuming<space/><link><target>animal product</target><trail>s</trail></link><space/>(milk, meat, eggs, etc.), from close or direct contact with animals or other humans, or through the environment.<extension extension_name='ref'><template><target>cite web</target><arg name="last">Schneider</arg><arg name="first">K</arg><arg name="last2">Garrett</arg><arg name="first2">L</arg><arg name="title">Non-therapeutic Use of Antibiotics in Animal Agriculture, Corresponding Resistance Rates, and What Can be Done About It</arg><arg name="url">http://www.cgdev.org/content/article/detail/1422307/</arg><arg name="publisher">Center for Global Development</arg><arg name="date">June 19, 2009</arg><arg name="ref">harv</arg></template></extension><space/>In the first pathway,<space/><link><target>food preservation</target></link><space/>methods can help eliminate, decrease, or prevent the growth of bacteria in some food classes. Evidence for the transfer of antibiotic-resistant microorganisms from animals to humans has been scant, and most evidence shows that pathogens of concern in human populations originated in humans and are maintained there, with rare cases of transference to humans.<extension extension_name='ref' name="pmid15151237"><template><target>cite journal</target><arg name="author"><space/>Hurd HS, Doores S, Hayes D, Mathew A, Maurer J, Silley P, Singer RS, Jones RN<space/></arg><arg name="title"><space/>Public health consequences of macrolide use in food animals: a deterministic risk assessment<space/></arg><arg name="journal"><space/>J. Food Prot.<space/></arg><arg name="volume"><space/>67<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>980–92<space/></arg><arg name="year"><space/>2004<space/></arg><arg name="pmid"><space/>15151237<space/></arg><arg name="doi"><space/></arg></template><template><target>subscription required</target></template></extension><extension extension_name='ref' name="pmid18643826"><template><target>cite journal</target><arg name="author"><space/>Hurd HS, Malladi S<space/></arg><arg name="title"><space/>A stochastic assessment of the public health risks of the use of macrolide antibiotics in food animals<space/></arg><arg name="journal"><space/>Risk Anal.<space/></arg><arg name="volume"><space/>28<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>695–710<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>18643826<space/></arg><arg name="doi"><space/>10.1111/j.1539-6924.2008.01054.x<space/></arg></template><template><target>subscription required</target></template></extension></paragraph><paragraph>The<space/><link><target>World Health Organization</target></link><space/>concluded that inappropriate use of antibiotics in animal husbandry is an underlying contributor to the emergence and spread of antibiotic-resistant germs, and that the use of antibiotics as growth promoters in animal feeds should be prohibited.<template><target>citation needed</target><arg name="date">January 2015</arg></template><space/>Regarding this matter, the<space/><link><target>World Organisation for Animal Health</target></link><space/>has added to the Terrestrial Animal Health Code a series of guidelines with recommendations to its members for the creation and harmonization of national antimicrobial resistance surveillance and monitoring programs,<extension extension_name='ref'><link type='external' href='http://www.oie.int/index.php?id=169&amp;amp;L=0&amp;amp;htmfile=chapitre_1.6.7.htm'>OIE, Terrestrial Animal Health Code</link></extension><template><target>full</target><arg name="date">January 2015</arg></template><space/>monitoring of the quantities of antibiotics used in animal husbandry,<extension extension_name='ref'><link type='external' href='http://www.oie.int/index.php?id=169&amp;amp;L=0&amp;amp;htmfile=chapitre_1.6.8.htm'>OIE,Terrestrial Animal Health Code</link></extension><template><target>full</target><arg name="date">January 2015</arg></template><space/>and recommendations to ensure the proper and prudent use of antibiotic substances. Another guideline is to implement methodologies that help to establish associated risk factors and assess the risk of antibiotic resistance.<extension extension_name='ref'><link type='external' href='http://www.oie.int/index.php?id=169&amp;amp;L=0&amp;amp;htmfile=chapitre_1.6.9.htm'>OIE,Terrestrial Animal Health Code</link></extension><template><target>full</target><arg name="date">January 2015</arg></template></paragraph><heading level='3'>Natural occurrence</heading><paragraph>Naturally occurring antibiotic resistance is common.<extension extension_name='ref' name="Wright10"><template><target>cite journal</target><arg name="author"><space/>Wright GD<space/></arg><arg name="title"><space/>Antibiotic resistance in the environment: a link to the clinic?<space/></arg><arg name="journal"><space/>Current Opinion in Microbiology<space/></arg><arg name="volume"><space/>13<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>589–94<space/></arg><arg name="date"><space/>October 2010<space/></arg><arg name="pmid"><space/>20850375<space/></arg><arg name="doi"><space/>10.1016/j.mib.2010.08.005<space/></arg></template><template><target>subscription required</target></template></extension><space/>Genes for resistance to antibiotics, like antibiotics themselves, are ancient.<extension extension_name='ref'><template><target>cite journal</target><arg name="journal">Nature</arg><arg name="volume">477</arg><arg name="pages"><space/>457–461</arg><arg name="date">September 2011<space/></arg><arg name="doi">10.1038/nature10388</arg><arg name="issue">7365</arg><arg name="title">Antibiotic resistance is ancient<space/></arg><arg name="last1">D'Costa<space/></arg><arg name="first1">Vanessa</arg><arg name="last2">King</arg><arg name="first2">Christine<space/></arg><arg name="last3">Kalan</arg><arg name="first3">Lindsay</arg><arg name="last4">Morar</arg><arg name="first4">Mariya</arg><arg name="last5">Sung<space/></arg><arg name="first5">Wilson</arg><arg name="last6">Schwarz</arg><arg name="first6">Carsten</arg><arg name="last7">Froese</arg><arg name="first7">Duane</arg><arg name="last8">Zazula</arg><arg name="first8">Grant<space/></arg><arg name="last9">Calmels</arg><arg name="first9">Fabrice</arg><arg name="pmid">21881561</arg><arg name="ref">harv</arg><arg name="bibcode"><space/>2011Natur.477..457D</arg><arg name="last10">Debruyne</arg><arg name="first10">Regis</arg><arg name="last11">Golding<space/></arg><arg name="first11">G. Brian</arg><arg name="last12">Poinar</arg><arg name="first12">Hendrik N.</arg><arg name="last13">Wright</arg><arg name="first13">Gerard D.</arg></template></extension><template><target>rp</target><arg>457–461</arg></template>The genes that confer resistance are known as the environmental<space/><link><target>resistome</target></link>.<extension extension_name='ref' name="Wright10"></extension><space/>These genes may be transferred from non-disease-causing bacteria to those that do cause disease, leading to clinically significant antibiotic resistance.<extension extension_name='ref' name="Wright10"></extension><space/>In 1952 it was shown that penicillin-resistant bacteria existed before penicillin treatment;<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://evolution.berkeley.edu/evolibrary/article/mutations_07</arg><arg name="title">Mutations are random</arg><arg name="publisher">University of California</arg><arg name="accessdate">Aug 14, 2011</arg></template></extension><space/>and also preexistent bacterial resistance to<space/><link><target>streptomycin</target></link>.<extension extension_name='ref'>Richard William Nelson.<space/><italics>Darwin, Then and Now: The Most Amazing Story in the History of Science</italics>, iUniverse, 2009, p. 294</extension><space/>In 1962, the presence of<space/><link><target>penicillinase</target></link><space/>was detected in dormant<space/><link><target>endospore</target><trail>s</trail></link><space/>of<space/><italics><link><target>Bacillus licheniformis</target></link></italics>, revived from dried soil on the roots of plants, preserved since 1689 in the<space/><link><target>British Museum</target></link>.<extension extension_name='ref'>Wayne W. Umbreit,<space/><italics>Advances in Applied Microbiology</italics>, vol. 11, Academic Press, 1970, p. 80</extension><extension extension_name='ref' name="pmid4963324"><template><target>cite journal</target><arg name="author"><space/>Pollock MR<space/></arg><arg name="title"><space/>Origin and function of penicillinase: a problem in biochemical evolution<space/></arg><arg name="journal"><space/>[[British Medical Journal]]<space/></arg><arg name="volume"><space/>4<space/></arg><arg name="issue"><space/>5571<space/></arg><arg name="pages"><space/>71–7<space/></arg><arg name="year"><space/>1967<space/></arg><arg name="pmid"><space/>4963324<space/></arg><arg name="pmc"><space/>1748446<space/></arg><arg name="doi"><space/>10.1136/bmj.4.5571.71</arg><arg name="url"><space/></arg></template><template><target>subscription required</target></template></extension><extension extension_name='ref' name="penicillinase"><italics><link><target>New Scientist</target></link></italics>, Jun 8, 1972, p. 546</extension><space/>Six<space/><link><target>Strain (biology)</target><part>strains</part></link><space/>of<space/><italics><link><target>Clostridium</target></link></italics>, found in the bowels of William Braine and John Hartnell (members of the<space/><link><target>Franklin Expedition</target></link>) showed resistance to<space/><link><target>cefoxitin</target></link><space/>and<space/><link><target>clindamycin</target></link>.<extension extension_name='ref' name="NS"><italics><link><target>New Scientist</target></link></italics>, Feb 11, 1989, p. 34</extension><space/>Penicillinase may have emerged as a defense mechanism for bacteria in their<space/><link><target>habitat</target><trail>s</trail></link>, such as the case of penicillinase-rich<space/><italics><link><target>Staphylococcus aureus</target></link></italics>, living with penicillin-producing<space/><italics><link><target>Trichophyton</target></link></italics>, however this may be circumstantial.<extension extension_name='ref' name="penicillinase"></extension><space/>Search for a penicillinase ancestor has focused on the class of<space/><link><target>protein</target><trail>s</trail></link><space/>that must be<space/><italics>a priori</italics><space/>capable of specific combination with<space/><link><target>penicillin</target></link>.<extension extension_name='ref'>Pollock, p. 77</extension><space/>The resistance to cefoxitin and clindamycin in turn was attributed to Braine's and Hartnell's contact with microorganisms that naturally produce them or<space/><link><target>random mutation</target></link><space/>in the<space/><link><target>chromosomes</target></link><space/>of<space/><italics>Clostridium</italics><space/>strains.<extension extension_name='ref' name="NS"></extension><space/>There is evidence that<space/><link><target>heavy metals</target></link><space/>and other pollutants may select for antibiotic-resistant bacteria, generating a constant source of them in small numbers.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Sieler</arg><arg name="first1">Claudia</arg><arg name="last2">Berendonk</arg><arg name="first2">Thomas U</arg><arg name="title">Heavy metal driven co-selection of antibiotic resistance in soil and water bodies impacted by agriculture and aquaculture</arg><arg name="journal">Frontiers in Microbiology</arg><arg name="date">December 14, 2012</arg><arg name="volume">3</arg><arg name="page">399</arg><arg name="doi">10.3389/fmicb.2012.00399</arg><arg name="pmid">23248620</arg><arg name="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522115/</arg><arg name="accessdate">14 July 2015</arg></template></extension><extension extension_name='ref'>Abigail A. Salyers, Dixie D. Whitt.<space/><italics>Revenge of the microbes: how bacterial resistance is undermining the antibiotic miracle</italics>, ASM Press, 2005, 186 pp, no e-book, ISBN 1555812988</extension><template><target>rp</target><arg>34</arg></template><template><target>better source</target><arg name="date">January 2015</arg></template></paragraph><heading level='2'>Environmental impact</heading><paragraph>Antibiotic resistance is a growing problem among humans and wildlife in terrestrial or aquatic environments. In this respect, the spread and contamination of the environment, especially through &quot;hot spots&quot; such as hospital wastewater and untreated urban wastewater, is a growing and serious public health problem.<extension extension_name='ref'><template><target>Cite journal</target><arg name="title"><space/>Factors impacting on the problem of antibiotic resistance</arg><arg name="url"><space/>http://jac.oxfordjournals.org/content/49/1/25</arg><arg name="journal"><space/>Journal of Antimicrobial Chemotherapy</arg><arg name="date"><space/>2002-01-01</arg><arg name="issn"><space/>0305-7453</arg><arg name="pmid"><space/>11751763</arg><arg name="pages"><space/>25-30</arg><arg name="volume"><space/>49</arg><arg name="issue"><space/>1</arg><arg name="doi"><space/>10.1093/jac/49.1.25</arg><arg name="language"><space/>en</arg><arg name="first"><space/>Stuart B.</arg><arg name="last"><space/>Levy</arg></template></extension><space/>Antibiotics have been polluting the environment since their introduction through human waste (medication, farming), animals, and the pharmaceutical industry.<extension extension_name='ref' name="Martinez, J. L. 2012 pp. 151- 171">Martinez, J. L., &amp; Olivares, J. (2012). Envrironmental Pollution By Antibiotic Resistance Genes. In P. L. Keen, &amp; M. H. Montforts, Antimicrobial Resistance in the Environment (pp. 151- 171). Hoboken, N.J.: John Wiley &amp; Sons.</extension><space/>Along with antibiotic waste, resistant bacteria follow, thus introducing antibiotic-resistant bacteria into the environment. As bacteria replicate quickly, the resistant bacteria that enter the environment replicate their resistance genes as they continue to divide. In addition, bacteria carrying resistance genes have the ability to spread those genes to other species via horizontal gene transfer. Therefore, even if the specific antibiotic is no longer introduced into the environment, antibiotic-resistance genes will persist through the bacteria that have since replicated without continuous exposure.<extension extension_name='ref' name="Martinez, J. L. 2012 pp. 151- 171"></extension></paragraph><paragraph>A study the<space/><link><target>Poudre River</target></link><space/>(<link><target>Colorado</target></link>,<space/><link><target>United States</target></link>) implicated wastewater treatment plants, as well as animal-feeding operations in the dispersal of antibiotic-resistance genes into the environment.<extension extension_name='ref'>Pruden, A., &amp; Arabi, M. (2012). Quantifying Anthropogenic Impacts on Environmental Reservoirs of Antibiotic Resistance. In P. L. Keen, &amp; M. H. Montforts, Antimicrobial Resistance in the Environment (pp. 173202). Hoboken, N.J.: John Wiley &amp; Sons.</extension><space/>This research was done using molecular signatures in order to determine the sources, and the location at the Poudre River was chosen due to lack of other anthropogenic influences upstream. The study indicates that monitoring of antibiotic-resistance genes may be useful in determining not only the point of origin of their release but also how these genes persist in the environment. In addition, studying physical and chemical methods of treatment may alleviate pressure of antibiotic-resistance genes in the environment, and thus their entry back into human contact.</paragraph><heading level='2'>Prevention</heading><paragraph><link><target>File:Antibioticresistance diagram.png</target><part>thumb</part><part>350px</part><part>Mission Critical: Preventing Antibiotic Resistance (CDC report, 2014)</part></link></paragraph><heading level='3'>World Health Organization</heading><paragraph>In 2014, the<space/><link><target>World Health Organization</target><part>WHO</part></link><space/>stated:<extension extension_name='ref' name="who.int"></extension></paragraph><list type='bullet'><listitem>People can help tackle resistance by:<list type='bullet'><listitem>using antibiotics only when prescribed by a doctor;</listitem><listitem>completing the full prescription, even if they feel better;</listitem><listitem>never sharing antibiotics with others or using leftover prescriptions.</listitem></list></listitem><listitem>Health workers and pharmacists can help tackle resistance by:<list type='bullet'><listitem>enhancing infection prevention and control;</listitem><listitem>only prescribing and dispensing antibiotics when they are truly needed;</listitem><listitem>prescribing and dispensing the right antibiotic(s) to treat the illness.</listitem></list></listitem><listitem>Policymakers can help tackle resistance by:<list type='bullet'><listitem>strengthening resistance tracking and laboratory capacity;</listitem><listitem>regulating and promoting appropriate use of medicines.</listitem></list></listitem><listitem>Policymakers and industry can help tackle resistance by:<list type='bullet'><listitem>fostering innovation and research and development of new tools;</listitem><listitem>promoting cooperation and information sharing among all stakeholders.</listitem></list></listitem></list><heading level='3'>Duration of antibiotics</heading><paragraph>Antibiotic treatment duration should be based on the infection and other health problems a person may have. For many infections once a person has improved there is little evidence that stopping treatment causes more resistance. Some therefore feel that stopping early may be reasonable in some cases. Other infections; however, do require long courses regardless of whether a person feels better.<extension extension_name='ref' name="NPS2013"></extension></paragraph><heading level='3'>Antibiotic usage</heading><paragraph>The<space/><link><target>Netherlands</target></link><space/>has the lowest rate of antibiotic prescribing in the<space/><link><target>OECD</target></link>, at a rate of 11.4 defined daily doses (DDD) per 1,000 people per day in 2011.<space/><link><target>Germany</target></link><space/>and<space/><link><target>Sweden</target></link><space/>also have lower prescribing rates, with Sweden's rate having been declining since 2007. By contrast,<space/><link><target>Greece</target></link>,<space/><link><target>France</target></link><space/>and<space/><link><target>Belgium</target></link><space/>have high prescribing rates of more than 28 DDD.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Indicator: Antibiotic prescribing</arg><arg name="url">http://www.qualitywatch.org.uk/indicator/antibiotic-prescribing#vis-ref_585</arg><arg name="website">QualityWatch</arg><arg name="publisher">Nuffield Trust & Health Foundation</arg><arg name="accessdate">16 July 2015</arg></template></extension><space/>It is unclear if rapid viral testing affects antibiotic use in children.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Doan</arg><arg name="first1">Q</arg><arg name="last2">Enarson</arg><arg name="first2">P</arg><arg name="last3">Kissoon</arg><arg name="first3">N</arg><arg name="last4">Klassen</arg><arg name="first4">TP</arg><arg name="last5">Johnson</arg><arg name="first5">DW</arg><arg name="title">Rapid viral diagnosis for acute febrile respiratory illness in children in the Emergency Department.</arg><arg name="journal">The Cochrane database of systematic reviews</arg><arg name="date">Sep 15, 2014</arg><arg name="volume">9</arg><arg name="pages">CD006452</arg><arg name="pmid">25222468</arg><arg name="doi">10.1002/14651858.CD006452.pub4</arg></template></extension></paragraph><heading level='3'>Strategies</heading><paragraph>Excessive antibiotic use has become one of the top contributors to the development of antibiotic resistance. Since the beginning of the antibiotic era, antibiotics have been used to treat a wide range of disease.<extension extension_name='ref' name="Andersson2011"><template><target>cite journal</target><arg name="author"><space/>Andersson D, Hughes D<space/></arg><arg name="title"><space/>Persistence of antibiotic resistance in bacterial populations<space/></arg><arg name="journal"><space/>FEMS Microbiol Rev<space/></arg><arg name="volume"><space/>35<space/></arg><arg name="pages"><space/>901–911<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="doi">10.1111/j.1574-6976.2011.00289.x</arg></template></extension><space/>Overuse of antibiotics has become the primary cause of rising levels of antibiotic resistance. The main problem is that doctors are willing to prescribe antibiotics to ill-informed individuals who believe that antibiotics can cure nearly all illnesses, including viral infections like the common cold. In an analysis of drug prescriptions, 36% of individuals with a cold or an upper respiratory infection (both viral in origin) were given prescriptions for antibiotics.<extension extension_name='ref' name="Gilberg2003"><template><target>cite journal</target><arg name="author"><space/>Gilberg K, Laouri M, Wade S, and Isonaka S<space/></arg><arg name="title"><space/>Analysis of medication use patterns: apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression, and CHF<space/></arg><arg name="journal"><space/>J Managed Care Pharm<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="pages"><space/>232–237<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension><space/>These prescriptions accomplished nothing other than increasing the risk of further evolution of antibiotic resistant bacteria.</paragraph><paragraph>In a recent years,<space/><link><target>antimicrobial stewardship</target></link><space/>teams in hospitals have encouraged optimal use of antimicrobials.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Doron</arg><arg name="first1">S</arg><arg name="last2">Davidson</arg><arg name="first2">LE</arg><arg name="title">Antimicrobial stewardship.</arg><arg name="journal">Mayo Clinic proceedings</arg><arg name="date">November 2011</arg><arg name="volume">86</arg><arg name="issue">11</arg><arg name="pages">1113–23</arg><arg name="pmid">22033257</arg><arg name="PMC">3203003</arg><arg name="accessdate">7 March 2015</arg><arg name="doi">10.4065/mcp.2011.0358</arg></template></extension><space/>The goals of antimicrobial stewardship are to help practitioners pick the right drug at the right dose and duration of therapy while preventing misuse and minimizing the development of resistance.</paragraph><paragraph>There have been increasing public calls for global collective action to address the threat, including a proposal for international treaty on antimicrobial resistance. Further detail and attention is still needed in order to recognize and measure trends in resistance on the international level; the idea of a global tracking system has been suggested but implementation has yet to occur. A system of this nature would provide insight to areas of high resistance as well as information necessary for evaluation of programs and other changes made to fight or reverse antibiotic resistance.</paragraph><paragraph>On March 27, 2015, the White House released a comprehensive plan to address the increasing need for agencies to combat the rise of antibiotic-resistant bacteria. The Task Force for Combating Antibiotic-Resistant Bacteria developed<space/><italics>The National Action Plan for Combating Antibiotic-Resistant Bacteria</italics><space/>with the intent of providing a roadmap to guide the US in the antibiotic resistance challenge and with hopes of saving many lives. This plan outlines steps taken by the Federal government over the next give years needed in order to prevent and contain outbreaks of antibiotic-resistant infections; maintain the efficacy of antibiotics already on the market; and to help to develop future diagnostics, antibiotics, and vaccines.<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>FACT SHEET: Obama Administration Releases National Action Plan to Combat Antibiotic-Resistant Bacteria</arg><arg name="url"><space/>https://www.whitehouse.gov/the-press-office/2015/03/27/fact-sheet-obama-administration-releases-national-action-plan-combat-ant</arg><arg name="website"><space/>whitehouse.gov</arg><arg name="accessdate"><space/>2015-10-30</arg></template></extension><space/></paragraph><paragraph>The Action Plan was developed around five goals with focuses on strengthening health care, public health veterinary medicine, agriculture, food safety and research, and manufacturing. These goals, as listed by the White House, are as follows:<space/></paragraph><list type='bullet'><listitem>Slow the Emergence of Resistant Bacteria and Prevent the Spread of Resistant Infections</listitem><listitem>Strengthen National One-Health Surveillance Efforts to Combat Resistance</listitem><listitem>Advance Development and use of Rapid and Innovative Diagnostic Tests for Identification and Characterization of Resistant Bacteria</listitem><listitem>Accelerate Basic and Applied Research and Development for New Antibiotics, Other Therapeutics, and Vaccines</listitem><listitem>Improve International Collaboration and Capacities for Antibiotic Resistance Prevention, Surveillance, Control and Antibiotic Research and Development</listitem></list><paragraph>By following are goals set to meet by 2020:<extension extension_name='ref'><template><target>Cite web</target><arg name="title"><space/>FACT SHEET: Obama Administration Releases National Action Plan to Combat Antibiotic-Resistant Bacteria</arg><arg name="url"><space/>https://www.whitehouse.gov/the-press-office/2015/03/27/fact-sheet-obama-administration-releases-national-action-plan-combat-ant</arg><arg name="website"><space/>whitehouse.gov</arg><arg name="accessdate"><space/>2015-10-30</arg></template></extension></paragraph><list type='bullet'><listitem>Establishment of antimicrobial programs within acute care hospital settings</listitem><listitem>Reduction of inappropriate antibiotic prescription and use by at least 50% in outpatient settings and 20% inpatient settings</listitem><listitem>Establishment of State Antibiotic Resistance (AR) Prevention Programs in all 50 states<space/></listitem><listitem>Elimination of the use of medically-important antibiotics for growth promotion in food-producing animals.</listitem></list><heading level='4'>Vaccines</heading><paragraph>Microorganisms do not develop resistance to<space/><link><target>vaccine</target><trail>s</trail></link><space/>because a vaccine enhances the body's immune system, whereas an antibiotic operates separately from the body's normal defenses. Furthermore, if the use of vaccines increase, there is evidence that antibiotic resistant strains of pathogens will decrease; the need for antibiotics will naturally decrease as vaccines prevent infection before it occurs.<space/><extension extension_name='ref'><template><target>Cite journal</target><arg name="title"><space/>Vaccines and antibiotic resistance</arg><arg name="url"><space/>http://www.ncbi.nlm.nih.gov/pubmed/22981392</arg><arg name="journal"><space/>Current Opinion in Microbiology</arg><arg name="date"><space/>2012-10-01</arg><arg name="issn"><space/>1879-0364</arg><arg name="pmid"><space/>22981392</arg><arg name="pages"><space/>596-602</arg><arg name="volume"><space/>15</arg><arg name="issue"><space/>5</arg><arg name="doi"><space/>10.1016/j.mib.2012.08.002</arg><arg name="first"><space/>Ravi P. N.</arg><arg name="last"><space/>Mishra</arg><arg name="first2"><space/>Ernesto</arg><arg name="last2"><space/>Oviedo-Orta</arg><arg name="first3"><space/>Prachi</arg><arg name="last3"><space/>Prachi</arg><arg name="first4"><space/>Rino</arg><arg name="last4"><space/>Rappuoli</arg><arg name="first5"><space/>Fabio</arg><arg name="last5"><space/>Bagnoli</arg></template></extension><space/>However, new strains that escape immunity induced by vaccines may<space/><link><target>Evolution</target><part>evolve</part></link>; for example, an updated<space/><link><target>influenza vaccine</target></link><space/>is needed each year.</paragraph><paragraph>While theoretically promising, antistaphylococcal vaccines have shown limited efficacy, because of immunological variation between<space/><italics>Staphylococcus</italics><space/>species, and the limited duration of effectiveness of the antibodies produced. Development and testing of more effective vaccines is underway.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.homesteadschools.com/nursing/courses/Immunity/Chapter05.html<space/></arg><arg name="title">Immunity, Infectious Diseases,and Pandemics—What You Can Do<space/></arg><arg name="publisher">HomesteadSchools.com<space/></arg><arg name="accessdate">2013-06-12</arg></template></extension></paragraph><heading level='4'>Alternating therapy</heading><paragraph>Alternating therapy is a proposed method in which two or three antibiotics are taken in a rotation versus taking just one antibiotic such that bacteria resistant to one antibiotic are killed when the next antibiotic is taken. Studies have found that this method reduces the rate at which antibiotic resistant bacteria emerge in vitro relative to a single drug for the entire duration.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Kim S, Lieberman TD, Kishony R<space/></arg><arg name="title"><space/>Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance<space/></arg><arg name="journal"><space/>PNAS<space/></arg><arg name="volume"><space/>111<space/></arg><arg name="issue"><space/>40<space/></arg><arg name="pages"><space/>14494–14499<space/></arg><arg name="year">2014<space/></arg><arg name="doi">10.1073/pnas.1409800111</arg><arg name="bibcode"><space/>2014PNAS..11114494K<space/></arg></template></extension></paragraph><heading level='4'>Develop new drugs</heading><paragraph>Since the discovery of antibiotics,<space/><link><target>research and development</target></link><space/>(R&amp;D) efforts have provided new drugs in time to treat bacteria that became resistant to older antibiotics, but in the 2000s there has been concern that development has slowed enough that seriously ill people may run out of treatment options.<extension extension_name='ref'><link type='external' href='https://www.wp.dh.gov.uk/publications/files/2013/03/CMO-Annual-Report-Volume-2-20111.pdf'>CMO Annual Report</link><space/><template><target>wayback</target><arg name="url">https://www.wp.dh.gov.uk/publications/files/2013/03/CMO-Annual-Report-Volume-2-20111.pdf<space/></arg><arg name="date">20150414174401<space/></arg></template></extension><space/>Another concern is that doctors may become reluctant to perform routine surgeries due to the increased risk of harmful infection.<extension extension_name='ref' name="obama"></extension><space/>Backup treatments can have serious side-effects; for example, treatment of multi-drug-resistant tuberculosis can cause deafness and insanity.<extension extension_name='ref'><link type='external' href='http://www.npr.org/2013/06/04/188566805/moldova-grapples-with-whether-to-isolate-tb-patients'>Moldova Grapples With Whether To Isolate TB Patients : NPR</link></extension><space/>The potential crisis at hand is the result of a marked decrease in industry R&amp;D.<extension extension_name='ref' name="bbc"><template><target>cite web</target><arg name="last">Walsh<space/></arg><arg name="first">Fergus<space/></arg><arg name="url">http://www.bbc.co.uk/news/health-21737844<space/></arg><arg name="title">BBC News&nbsp;— Antibiotics resistance 'as big a risk as terrorism' – medical chief<space/></arg><arg name="publisher">Bbc.co.uk<space/></arg><arg name="accessdate">2013-03-12</arg></template></extension><space/>Poor financial investment in antibiotic research has exacerbated the situation.<extension extension_name='ref' name="TheRealNews-2014-05-18"></extension><extension extension_name='ref' name="bbc"></extension><space/>In 2011,<space/><link><target>Pfizer</target></link>, one of the last major pharmaceutical companies developing new antibiotics, shut down its primary research effort, citing poor shareholder returns relative to drugs for chronic illnesses.<extension extension_name='ref' name="medpage"><template><target>cite web</target><arg name="last"><space/>Gever<space/></arg><arg name="first">John<space/></arg><arg name="url">http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/24708<space/></arg><arg name="title">Pfizer Moves May Dim Prospect for New Antibiotics<space/></arg><arg name="publisher">MedPage Today<space/></arg><arg name="date">2011-02-04<space/></arg><arg name="accessdate">2013-03-12</arg></template></extension></paragraph><paragraph>In the United States, drug companies and the administration of President<space/><link><target>Barack Obama</target></link><space/>have been proposing changing the standards by which the FDA approves antibiotics targeted at resistant organisms.<extension extension_name='ref' name="obama"><link type='external' href='http://www.npr.org/blogs/health/2013/06/04/188380562/obama-administration-seeks-to-loosen-antibiotic-approvals'>Obama Administration Seeks To Ease Approvals For Antibiotics : Shots Health News : NPR</link></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ledford H<space/></arg><arg name="title"><space/>FDA under pressure to relax drug rules<space/></arg><arg name="journal"><space/>Nature<space/></arg><arg name="volume"><space/>492<space/></arg><arg name="issue"><space/>7427<space/></arg><arg name="pages"><space/>19<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>23222585<space/></arg><arg name="doi"><space/>10.1038/492019a<space/></arg><arg name="bibcode"><space/>2012Natur.492...19L<space/></arg></template></extension><space/>On 12 December 2013, the Antibiotic Development to Advance Patient Treatment (ADAPT) Act of 2013 was introduced in the<space/><link><target>U.S. Congress</target></link>. The ADAPT Act aims to fast-track the drug development in order to combat the growing public health threat of 'superbugs'. Under this Act, the FDA can approve antibiotics and antifungals needed for life-threatening infections based on data from smaller clinical trials. The<space/><link><target>Centers for Disease Control and Prevention</target></link><space/>(CDC) will reinforce the monitoring of the use of antibiotics that treat serious and life-threatening infections and the emerging resistance, and make the data publicly available. The FDA antibiotics labeling process, 'Susceptibility Test Interpretive Criteria for Microbial Organisms' or 'breakpoints' is also streamlined to allow the most up-to-date and cutting-edge data available to healthcare professionals under the new Act.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://green.house.gov/press-release/green-gingrey-introduce-adapt-act-safeguard-public-health</arg><arg name="title">Green, Gingrey Introduce ADAPT Act to Safeguard Public Health</arg><arg name="author">Press Release</arg><arg name="publisher">U.S. Congress</arg><arg name="date">12 December 2013</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://assets.fiercemarkets.net/public/lifesciences/HR3742.pdf</arg><arg name="title">Antibiotic Development to Advance Patient Treatment Act of 2013</arg><arg name="publisher">U.S. Congress</arg><arg name="date">12 December 2013</arg></template></extension></paragraph><paragraph>On 18 September 2014 Obama signed an executive order<space/><extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.whitehouse.gov/the-press-office/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria</arg><arg name="title">Executive Order – Combating Antibiotics-Resistant Bacteria</arg><arg name="author">Office of the Press Secretary</arg><arg name="publisher">The White House</arg><arg name="date">18 September 2014</arg></template></extension><space/>to implement the recommendations proposed in a report<space/><extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf</arg><arg name="title">Report to the President on Combating Antibiotic Resistance</arg><arg name="author">President's Council of Advisors on Science and Technology</arg><arg name="publisher">PCAST</arg><arg name="date">September 2014</arg></template></extension><space/>by the<space/><link><target>President's Council of Advisors on Science and Technology</target></link><space/>(PCAST) which outlines strategies to stream-line clinical trials and speed up the R&amp;D of new antibiotics. Among the proposals:</paragraph><list type='bullet'><listitem>Create a 'robust, standing national clinical trials network for antibiotic testing' which will promptly enroll patients once identified to be suffering from dangerous bacterial infections. The network will allow testing multiple new agents from different companies simultaneously for their safety and efficacy.</listitem><listitem>Establish a 'Special Medical Use (SMU)' pathway for FDA to approve new antimicrobial agents for use in limited patient populations, shorten the approval timeline for new drug so patients with severe infections could benefit as quickly as possible.</listitem><listitem>Provide economic incentives, especially for development of new classes of antibiotics, to offset the steep R&amp;D costs which drive away the industry to develop antibiotics.</listitem></list><paragraph>The executive order also included a $20 million prize to encourage the development of diagnostic tests to identify highly resistant bacterial infections.<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.fiercebiotech.com/story/antibiotics-rd-get-critical-lift-executive-order-obama-advisory-group/2014-09-19?utm_campaign</arg><arg name="title">Antibiotics R & D to get critical lift by executive order, Obama advisory group</arg><arg name="author">Mullin, Emily</arg><arg name="publisher">fiercebiotech.com</arg><arg name="date">19 September 2014</arg><arg name="accessdate">22 September 2014</arg></template></extension></paragraph><paragraph>The U.S.<space/><link><target>National Institutes of Health</target></link><space/>plans to fund a new research network on the issue up to $62&amp;nbsp;million from 2013 to 2019.<extension extension_name='ref'><link type='external' href='http://www.nih.gov/news/health/jun2013/niaid-03.htm'>NIH to fund clinical research network on antibacterial resistance</link></extension><space/>Using authority created by the<space/><link><target>Pandemic and All Hazards Preparedness Act</target></link><space/>of 2006, the<space/><link><target>Biomedical Advanced Research and Development Authority</target></link><space/>in the U.S.<space/><link><target>Department of Health and Human Services</target></link><space/>announced that it will spend between $40&amp;nbsp;million and $200&amp;nbsp;million in funding for R&amp;D on new antibiotic drugs under development by<space/><link><target>GlaxoSmithKline</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.phe.gov/Preparedness/news/Pages/strategic-alliance-130522.aspx</arg><arg name="title">HHS forms strategic alliance to develop new antibiotics Approach provides a pipeline of new drugs rather than a single medical countermeasure</arg><arg name="author">Press Release</arg><arg name="publisher">Public Health Emergency, U.S. Department of Health & Human Services</arg><arg name="date">22 May 2013</arg></template></extension></paragraph><paragraph>One major cause of antibiotic resistance is the increased pumping activity of microbial<space/><link><target>ABC transporters</target></link>, which diminishes the effective drug concentration inside the microbial cell. ABC transporter inhibitors that can be used in combination with current antimicrobials are being tested in clinical trials and are available for therapeutic regimens.<extension extension_name='ref' name="Ponte-SucreA"><template><target>cite book</target><arg name="editor1-last">Ponte-Sucre<space/></arg><arg name="editor1-first">A<space/></arg><arg name="year">2009<space/></arg><arg name="title">ABC Transporters in Microorganisms<space/></arg><arg name="publisher">Caister Academic Press<space/></arg><arg name="isbn"><space/>978-1-904455-49-3</arg></template><template><target>page needed</target><arg name="date">November 2013</arg></template></extension><template><target>undue-inline</target><arg name="date">March 2015</arg></template></paragraph><heading level='3'>Animal use</heading><heading level='4'>Europe</heading><paragraph>In 1997, European Union health ministers voted to ban<space/><link><target>avoparcin</target></link><space/>and four additional antibiotics used to promote animal growth in 1999.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Casewell</arg><arg name="first1">M.</arg><arg name="title">The European ban on growth-promoting antibiotics and emerging consequences for human and animal health</arg><arg name="journal">Journal of Antimicrobial Chemotherapy</arg><arg name="date">1 July 2003</arg><arg name="volume">52</arg><arg name="issue">2</arg><arg name="pages">159–161</arg><arg name="doi">10.1093/jac/dkg313</arg></template></extension><space/>In 2006 a ban on the use of antibiotics in European feed, with the exception of two antibiotics in poultry feeds, became effective.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Castanon JI<space/></arg><arg name="title"><space/>History of the use of antibiotic as growth promoters in European poultry feeds<space/></arg><arg name="journal"><space/>Poult. Sci.<space/></arg><arg name="volume"><space/>86<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>2466–71<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17954599<space/></arg><arg name="doi"><space/>10.3382/ps.2007-00249<space/></arg><arg name="ref"><space/>harv<space/></arg></template><template><target>subscription required</target></template></extension><space/>In Scandinavia, there is evidence that the ban has led to a lower<space/><link><target>prevalence</target></link><space/>of antibiotic resistance in (nonhazardous) animal bacterial populations.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bengtsson B, Wierup M<space/></arg><arg name="title"><space/>Antimicrobial resistance in Scandinavia after ban of antimicrobial growth promoters<space/></arg><arg name="journal"><space/>Anim. Biotechnol.<space/></arg><arg name="volume"><space/>17<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>147–56<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>17127526<space/></arg><arg name="doi"><space/>10.1080/10495390600956920<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="last2"><space/>Wierup<space/></arg><arg name="first2"><space/>M.<space/></arg></template><template><target>subscription required</target></template></extension><space/>As of 2004, several European countries established a decline of antimicrobial resistance in humans through limiting the usage antimicrobials in agriculture and food industries without jeopardizing animal health or economic cost.<extension extension_name='ref'><template><target>Cite journal</target><arg name="title"><space/>Antimicrobial use in agriculture: controlling the transfer of antimicrobial resistance to humans1</arg><arg name="url"><space/>http://www.sciencedirect.com/science/article/pii/S1045187004000111</arg><arg name="journal"><space/>Seminars in Pediatric Infectious Diseases</arg><arg name="date"><space/>2004-04-01</arg><arg name="pages"><space/>78-85</arg><arg name="volume"><space/>15</arg><arg name="series"><space/>Problems and Solutions for Antimicrobial Resistance among Pediatric Respiratory Tract and Nosocomiall Pathogens</arg><arg name="issue"><space/>2</arg><arg name="doi"><space/>10.1053/j.spid.2004.01.010</arg><arg name="first"><space/>Frederick J</arg><arg name="last"><space/>Angulo</arg><arg name="first2"><space/>Nicole L</arg><arg name="last2"><space/>Baker</arg><arg name="first3"><space/>Sonja J</arg><arg name="last3"><space/>Olsen</arg><arg name="first4"><space/>Alicia</arg><arg name="last4"><space/>Anderson</arg><arg name="first5"><space/>Timothy J</arg><arg name="last5"><space/>Barrett</arg></template></extension></paragraph><heading level='4'>United States</heading><paragraph>The<space/><link><target>United States Department of Agriculture</target></link><space/>(USDA) and the<space/><link><target>Food and Drug Administration</target></link><space/>(FDA) collect data on antibiotic use in humans and in a more limited fashion in animals.<extension extension_name='ref' name="gao"><template><target>cite web</target><arg name="url">http://www.gao.gov/assets/330/323097.html</arg><arg name="title">GAO-11-801, Antibiotic Resistance: Agencies Have Made Limited Progress Addressing Antibiotic Use in Animals</arg><arg name="publisher">gao.gov</arg><arg name="accessdate">2014-01-25</arg></template></extension>The FDA first determined in 1977 that there is evidence of emergence of antibiotic-resistant bacterial strains in livestock. The long-established practice of permitting OTC sales of antibiotics (including penicillin and other drugs) to lay animal owners for administration to their own animals nonetheless continued in all states.In 2000, the FDA announced their intention to revoke approval of<space/><link><target>fluoroquinolone</target></link><space/>use in poultry production because of substantial evidence linking it to the emergence of fluoroquinolone-resistant<space/><italics><link><target>Campylobacter</target></link></italics><space/>infections in humans. Legal challenges from the food animal and pharmaceutical industries delayed the final decision to do so until 2006.<extension extension_name='ref' name="Nelson-2007"><template><target>cite journal</target><arg name="author"><space/>Nelson JM, Chiller TM, Powers JH, Angulo FJ<space/></arg><arg name="title"><space/>Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story<space/></arg><arg name="journal"><space/>Clin Infect Dis<space/></arg><arg name="volume"><space/>44<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>977–80<space/></arg><arg name="date"><space/>Apr 2007<space/></arg><arg name="pmid"><space/>17342653<space/></arg><arg name="doi"><space/>10.1086/512369<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension><space/>Fluroquinolones have been banned from extra-label use in food animals in the USA since 2007. However, they remain widely used in companion and exotic animals.</paragraph><paragraph>During 2007, two federal bills (S. 549<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.govtrack.us/congress/bill.xpd?bill</arg><arg name="title">US Senate Bill S. 549: Preservation of Antibiotics for Medical Treatment Act of 2007</arg><arg name="ref">harv</arg></template></extension><space/>and H.R. 962<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.govtrack.us/congress/bill.xpd?bill</arg><arg name="title">Preservation of Antibiotics for Medical Treatment Act of 2007</arg><arg name="ref">harv</arg></template></extension>) aimed at phasing out &quot;nontherapeutic&quot; antibiotics in U.S. food animal production. The Senate bill, introduced by Sen.<space/><link><target>Ted Kennedy</target><part>Edward &quot;Ted&quot; Kennedy</part></link>, died. The House bill, introduced by Rep.<space/><link><target>Louise Slaughter</target></link>, died after being referred to Committee.</paragraph><paragraph>In March 2012, the<space/><link><target>United States District Court for the Southern District of New York</target></link>, ruling in an action brought by the<space/><link><target>Natural Resources Defense Council</target></link><space/>and others, ordered the FDA to revoke approvals for the use of antibiotics in livestock that violated FDA regulations.<extension extension_name='ref' name="MPFDA"><template><target>cite news</target><arg name="title">FDA Told to Move on Antibiotic Use in Livestock</arg><arg name="url">http://www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/31792</arg><arg name="accessdate">March 24, 2012</arg><arg name="newspaper">MedPage Today</arg><arg name="date">March 23, 2012</arg><arg name="author">John Gever</arg></template></extension><space/>On April 11, 2012 the FDA announced a voluntary program to phase out unsupervised use of drugs as feed additives and convert approved over-the-counter uses for antibiotics to prescription use only, requiring veterinarian supervision of their use and a prescription.<extension extension_name='ref' name="NYTPrescription"><template><target>cite news</target><arg name="title">U.S. Tightens Rules on Antibiotics Use for Livestock</arg><arg name="url">http://www.nytimes.com/2012/04/12/us/antibiotics-for-livestock-will-require-prescription-fda-says.html</arg><arg name="accessdate">April 12, 2012</arg><arg name="newspaper">The New York Times</arg><arg name="date">April 11, 2012</arg><arg name="author">Gardiner Harris</arg></template></extension><extension extension_name='ref' name="FDAFAQ"><template><target>cite web</target><arg name="title">FDA's Strategy on Antimicrobial Resistance&nbsp;— Questions and Answers</arg><arg name="url">http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm216939.htm</arg><arg name="publisher">U.S. Food and Drug Administration</arg><arg name="accessdate">April 12, 2012</arg><arg name="date">April 11, 2012</arg><arg name="quote">"Judicious use" is using an antimicrobial drug appropriately and only when necessary; Based on a thorough review of the available scientific information, FDA recommends that use of medically important antimicrobial drugs in food-producing animals be limited to situations where the use of these drugs is necessary for ensuring animal health, and their use includes veterinary oversight or consultation. FDA believes that using medically important antimicrobial drugs to increase production in food-producing animals is not a judicious use.</arg></template></extension><space/>In December 2013, the FDA announced the commencement of these steps to phase out the use of antibiotics for the purposes of promoting livestock growth.<extension extension_name='ref' name="TheRealNews-2014-05-18"></extension><extension extension_name='ref'><template><target>cite web</target><arg name="last">Tavernise</arg><arg name="first">Sabrina</arg><arg name="title">F.D.A. to Phase Out Use of Some Antibiotics in Animals Raised for Meat</arg><arg name="url">http://www.nytimes.com/2013/12/12/health/fda-to-phase-out-use-of-some-antibiotics-in-animals-raised-for-meat.html</arg><arg name="publisher">[[The New York Times]]</arg><arg name="accessdate">11 December 2013</arg></template></extension></paragraph><paragraph>Growing U.S. consumer concern about using antibiotics in animal feed has led to greater availability of &quot;antibiotic-free&quot; animal products. For example, chicken producer Perdue removed all human antibiotics from its feed and launched products labeled antibiotic free under the Harvestland brand in 2007. Consumer response was positive, and in 2014 Perdue also phased out ionophores from its hatchery and began using the antibiotic free labels on its Harvestland, Simply Smart, and Perfect Portions products.<extension extension_name='ref'><template><target>cite news</target><arg name="title">Perdue Sharply Cuts Antibiotic Use in Chickens and Jabs at Its Rivals</arg><arg name="url">http://www.nytimes.com/2015/08/01/business/perdue-and-the-race-to-end-antibiotic-use-in-chickens.html</arg><arg name="accessdate">August 12, 2015</arg><arg name="newspaper">The New York Times</arg><arg name="date">July 31, 2015</arg><arg name="author">Stephanie Strom</arg></template></extension></paragraph><heading level='2'>Mechanisms</heading><paragraph><template><target>see also</target><arg>Microevolution</arg></template><link><target>File:Antibiotic resistance.svg</target><part>thumb</part><part>right</part><part>Schematic representation of how antibiotic resistance evolves via natural selection. The top section represents a population of bacteria before exposure to an antibiotic. The middle section shows the population directly after exposure, the phase in which selection took place. The last section shows the distribution of resistance in a new generation of bacteria. The legend indicates the resistance levels of individuals.</part></link></paragraph><paragraph><link><target>File:mecA Resistance.svg</target><part>thumb</part><part>right</part><part>Diagram depicting antibiotic resistance through alteration of the antibiotic's target site, modeled after MRSA's resistance to penicillin. Beta-lactam antibiotics permanently inactivate<space/><link><target>Penicillin-binding protein</target><part>PBP enzymes</part></link>, which are essential for bacterial life, by permanently binding to their active sites.<space/><link><target>Methicillin-resistant Staphylococcus aureus</target><part>MRSA</part></link>, however, expresses a PBP that does not allow the antibiotic into its active site.</part></link></paragraph><paragraph>The four main mechanisms by which microorganisms exhibit resistance to antimicrobials are:</paragraph><list type='numbered'><listitem>Drug inactivation or modification: for example, enzymatic deactivation of<space/><link><target>Penicillin</target><part>''penicillin'' G</part></link><space/>in some penicillin-resistant bacteria through the production of<space/><link><target>Beta-lactamases</target><part>-lactamases</part></link>. Most commonly, the protective enzymes produced by the bacterial cell will add an acetyl or phosphate group to a specific site on the antibiotic, which will reduce its ability to bind to the bacterial ribosomes and disrupt protein synthesis.<extension extension_name='ref' name="Criswell, Daniel 2004">[Criswell, Daniel. &quot;The &quot;Evolution&quot; of Antibiotic Resistance.&quot; Institute for Creation Research. N.p., 2004. Web. 28 Oct. 2014.]</extension></listitem><listitem>Alteration of target site: for example, alteration of<space/><link><target>Penicillin binding protein</target><part>PBP</part></link>the binding target site of penicillinsin<space/><link><target>Methicillin-resistant Staphylococcus aureus</target><part>MRSA</part></link><space/>and other penicillin-resistant bacteria. Another protective mechanism found among bacterial species is ribosomal protection proteins. These proteins protect the bacterial cell from antibiotics that target the cells ribosomes to inhibit protein synthesis. The mechanism involves the binding of the ribosomal protection proteins to the ribosomes of the bacterial cell, which in turn changes its conformational shape. This allows the ribosomes to continue synthesizing proteins essential to the cell while preventing antibiotics from binding to the ribosome to inhibit protein synthesis.<space/></listitem><listitem>Alteration of metabolic pathway: for example, some<space/><link><target>sulfa drugs</target><part>sulfonamide</part></link>-resistant bacteria do not require<space/><link><target>para-aminobenzoic acid</target></link><space/>(PABA), an important precursor for the synthesis of<space/><link><target>folic acid</target></link><space/>and<space/><link><target>nucleic acids</target></link><space/>in bacteria inhibited by sulfonamides, instead, like mammalian cells, they turn to using preformed folic acid.</listitem><listitem>Reduced drug accumulation: by decreasing drug<space/><link><target>Semipermeable membrane</target><part>permeability</part></link><space/>or increasing active<space/><link><target>efflux (microbiology)</target><part>efflux</part></link><space/>(pumping out) of the drugs across the cell surface<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Li XZ, Nikaido H<space/></arg><arg name="title"><space/>Efflux-Mediated Drug Resistance in Bacteria: an Update<space/></arg><arg name="journal"><space/>Drug<space/></arg><arg name="volume"><space/>69<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1555–623<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19678712<space/></arg><arg name="pmc"><space/>2847397<space/></arg><arg name="doi"><space/>10.2165/11317030-000000000-00000<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="last2"><space/>Nikadio<space/></arg><arg name="first2"><space/>H<space/></arg></template></extension><space/>These specialized pumps can be found within the cellular membrane of certain bacterial species and are used to pump antibiotics out of the cell before they are able to do any damage. These efflux pumps are often activated by a specific substrate associated with an antibiotic.<extension extension_name='ref'>[RI Aminov, RI Mackie. Evolution and ecology of antibiotic resistance genes. Microbiology Letters. 8 May 2007.<space/><template><target>DOI</target><arg>10.1111/j.1574-6968.2007.00757.x]</arg></template></extension></listitem></list><paragraph><link><target>File:Antibiotic resistance mechanisms.jpg</target><part>thumb</part><part>300x300px</part><part>A number of mechanisms used by common antibiotics to deal with bacteria and ways by which bacteria become resistant to them.</part></link>Antibiotic resistance can be a result of<space/><link><target>horizontal gene transfer</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Ochiai</arg><arg name="first"><space/>K.</arg><arg name="last2"><space/>Yamanaka</arg><arg name="first2"><space/>T<space/></arg><arg name="last3">Kimura<space/></arg><arg name="first3">K<space/></arg><arg name="last4">Sawada</arg><arg name="first4"><space/>O<space/></arg><arg name="year">1959</arg><arg name="title"><space/>Inheritance of drug resistance (and its transfer) between Shigella strains and Between Shigella and E.coli strains</arg><arg name="journal"><space/>Hihon Iji Shimpor,<space/></arg><arg name="page"><space/>1861</arg><arg name="volume"><space/>34</arg><arg name="language"><space/>Japanese</arg><arg name="ref">harv</arg></template></extension><space/>and also of unlinked point mutations in the<space/><link><target>pathogen</target></link><space/><link><target>genome</target></link><space/>at a rate of about 1 in 10<xhtml:sup>8</xhtml:sup><space/>per chromosomal replication. Mutations are rare but the fact that bacteria reproduce at such a high rate allows for the effect to be significant. A mutation may produce a change in the binding site of the antibiotic, which may allow the site to continue proper functioning in the presence of the antibiotic or prevent the binding of the antibiotic to the site altogether. Research has shown the bacterial protein LexA may play a key role in the acquisition of bacterial mutations giving resistance to quinolones and rifampicin. DNA damage induces the SOS gene repressor LexA to undergo autoproteolytic activity. This includes the transcription of genes encoding Pol II, Pol IV, and Pol V, which are three nonessential DNA polymerases that are required for mutation in response to DNA damage.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Cirz RT, Chin JK, Andes DR, de Crécy-Lagard V, Craig WA, Romesberg FE<space/></arg><arg name="title"><space/>Inhibition of Mutation and Combating the Evolution of Antibiotic Resistance<space/></arg><arg name="journal"><space/>PLoS Biol.<space/></arg><arg name="volume"><space/>3<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>e176<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>15869329<space/></arg><arg name="pmc"><space/>1088971<space/></arg><arg name="doi"><space/>10.1371/journal.pbio.0030176<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension><space/>The antibiotic action against the pathogen can be seen as an environmental pressure. Those bacteria with a mutation that allows them to survive live to reproduce. They then pass this trait to their offspring, which leads to the evolution of a fully resistant colony. Although these chromosomal mutations may seem to benefit the bacteria by providing antibiotic resistance, they also confer a cost of fitness. For example, a ribosomal mutation may protect a bacterial cell by changing the binding site of an antibiotic but it will also slow the process of protein synthesis.<extension extension_name='ref' name="Criswell, Daniel 2004"></extension><space/>Additionally, a particular study specifically compared the overall fitness of antibiotic resistant strains of Escherichia coli and Salmonella typhimurium to their drug-sensitive revertants. They observed a reduced overall fitness in the antibiotic resistant strains, especially in growth rate.<extension extension_name='ref'>BR Levin, V Perrot, Nina Walker. Compensatory Mutations, Antibiotic Resistance and the Population Genetics of Adaptive Evolution in Bacteria. Genetics March 1, 2000 vol. 154 no. 3 985997.</extension></paragraph><paragraph>There are three known mechanisms of<space/><link><target>fluoroquinolone</target></link><space/>resistance. Some types of<space/><link><target>Efflux (microbiology)</target><part>efflux</part></link><space/>pumps can act to decrease intracellular<space/><link><target>quinolone</target></link><space/>concentration.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Morita Y, Kodama K, Shiota S, Mine T, Kataoka A, Mizushima T, Tsuchiya T<space/></arg><arg name="title"><space/>NorM, a Putative Multidrug Efflux Protein, of Vibrio parahaemolyticus and Its Homolog in Escherichia coli<space/></arg><arg name="journal"><space/>Antimicrob. Agents Chemother.<space/></arg><arg name="volume"><space/>42<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>1778–82<space/></arg><arg name="date"><space/>July 1998<space/></arg><arg name="pmid"><space/>9661020<space/></arg><arg name="pmc"><space/>105682<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension><space/>In Gram-negative bacteria, plasmid-mediated resistance genes produce proteins that can bind to<space/><link><target>DNA gyrase</target></link>, protecting it from the action of quinolones. Finally, mutations at key sites in DNA gyrase or<space/><link><target>topoisomerase IV</target></link><space/>can decrease their binding affinity to quinolones, decreasing the drug's effectiveness.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Robicsek A, Jacoby GA, Hooper DC<space/></arg><arg name="title"><space/>The worldwide emergence of plasmid-mediated quinolone resistance<space/></arg><arg name="journal"><space/>Lancet Infect Dis<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>629–40<space/></arg><arg name="date"><space/>October 2006<space/></arg><arg name="pmid"><space/>17008172<space/></arg><arg name="doi"><space/>10.1016/S1473-3099(06)70599-0<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="last3"><space/>Hooper<space/></arg><arg name="last2"><space/>Jacoby<space/></arg><arg name="first2"><space/>GA<space/></arg><arg name="first3"><space/>DC<space/></arg></template></extension></paragraph><paragraph>Antibiotic resistance can also be introduced artificially into a microorganism through laboratory protocols, sometimes used as a<space/><link><target>selectable marker</target></link><space/>to examine the mechanisms of gene transfer or to identify individuals that absorbed a piece of DNA that included the resistance gene and another gene of interest. A recent study demonstrated that the extent of<space/><link><target>horizontal gene transfer</target></link><space/>among<space/><italics>Staphylococcus</italics><space/>is much greater than previously expectedand encompasses genes with functions beyond antibiotic resistance and virulence, and beyond genes residing within the<space/><link><target>mobile genetic elements</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Chan CX, Beiko RG, Ragan MA<space/></arg><arg name="title"><space/>Lateral Transfer of Genes and Gene Fragments in Staphylococcus Extends beyond Mobile Elements<space/></arg><arg name="journal"><space/>J Bacteriol<space/></arg><arg name="volume"><space/>193<space/></arg><arg name="issue"><space/>15<space/></arg><arg name="pages"><space/>3964–3977<space/></arg><arg name="date"><space/>August 2011<space/></arg><arg name="pmid"><space/>21622749<space/></arg><arg name="pmc"><space/>3147504<space/></arg><arg name="doi"><space/>10.1128/JB.01524-10<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="last3"><space/>Ragan<space/></arg><arg name="last2"><space/>Beiko<space/></arg><arg name="first2"><space/>RG<space/></arg><arg name="first3"><space/>MA<space/></arg></template></extension></paragraph><paragraph>For a long time, it has been thought that, for a microorganism to become resistant to an antibiotic, it must be in a large population. However, recent findings show that there is no necessity of large populations of bacteria for the appearance of antibiotic resistance. We know now that small populations of E.coli in an antibiotic gradient can become resistant. Any heterogeneous environment with respect to nutrient and antibiotic gradients may facilitate the development of antibiotic resistance in small bacterial populations and this is also true for the human body. Researchers hypothesize that the mechanism of resistance development is based on four SNP mutations in the genome of E.coli produced by the gradient of antibiotic. These mutations confer the bacteria emergence of antibiotic resistance.</paragraph><heading level='2'>Organisms</heading><heading level='3'>Bacteria</heading><heading level='4'><italics>Staphylococcus aureus</italics></heading><paragraph><template><target>Main</target><arg>Methicillin-resistant Staphylococcus aureus</arg></template></paragraph><paragraph><italics><link><target>Staphylococcus aureus</target></link></italics><space/>(colloquially known as &quot;Staph aureus&quot; or a &quot;Staph infection&quot;) is one of the major resistant pathogens. Found on the<space/><link><target>mucous membranes</target></link><space/>and the<space/><link><target>human skin</target></link><space/>of around a third of the population, it is extremely adaptable to antibiotic pressure. It was one of the earlier bacteria in which<space/><link><target>penicillin</target></link><space/>resistance was foundin 1947, just four years after the drug started being mass-produced.<space/><link><target>Methicillin</target></link><space/>was then the antibiotic of choice, but has since been replaced by<space/><link><target>oxacillin</target></link><space/>due to significant kidney toxicity.<space/><link><target>Methicillin-resistant Staphylococcus aureus</target><part>Methicillin-resistant ''Staphylococcus aureus''</part></link><space/>(MRSA) was first detected in Britain in 1961, and is now &quot;quite common&quot; in hospitals. MRSA was responsible for 37% of fatal cases of<space/><link><target>sepsis</target></link><space/>in the<space/><link><target>United Kingdom</target><part>UK</part></link><space/>in 1999, up from 4% in 1991. Half of all<space/><italics>S. aureus</italics><space/>infections in the<space/><link><target>United States</target><part>US</part></link><space/>are resistant to penicillin, methicillin,<space/><link><target>tetracycline</target></link><space/>and<space/><link><target>erythromycin</target></link>.</paragraph><paragraph>This left<space/><link><target>vancomycin</target></link><space/>as the only effective agent available at the time. However, strains with intermediate (48&amp;nbsp;g/ml) levels of resistance, termed glycopeptide-intermediate<space/><italics>Staphylococcus aureus</italics><space/>(GISA) or vancomycin-intermediate<space/><italics>Staphylococcus aureus</italics><space/>(VISA), began appearing in the late 1990s. The first identified case was in Japan in 1996, and strains have since been found in hospitals in England, France and the US. The first documented strain with complete (&gt;16&amp;nbsp;g/ml) resistance to vancomycin, termed<space/><link><target>Vancomycin-resistant Staphylococcus aureus</target><part>vancomycin-resistant ''Staphylococcus aureus''</part></link><space/>(VRSA) appeared in the United States in 2002.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC<space/></arg><arg name="title"><space/>Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center<space/></arg><arg name="journal"><space/>Journal of Antimicrobial Chemotherapy<space/></arg><arg name="volume"><space/>52<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>864–868<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>14563898<space/></arg><arg name="doi"><space/>10.1093/jac/dkg457<space/></arg></template></extension><space/>However, in 2011, a variant of vancomycin has been tested that binds to the lactate variation and also binds well to the original target, thus reinstating potent antimicrobial activity.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Xie J, Pierce JG, James RC, Okano A, Boger DL<space/></arg><arg name="title"><space/>A Redesigned Vancomycin Engineered for Dual d-Ala-d-Ala and d-Ala-d-Lac Binding Exhibits Potent Antimicrobial Activity Against Vancomycin-Resistant Bacteria<space/></arg><arg name="journal"><space/>J. Am. Chem. Soc. 133,<space/></arg><arg name="volume"><space/>133<space/></arg><arg name="issue"><space/>35<space/></arg><arg name="pages"><space/>13946–9<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="pmid"><space/>21823662<space/></arg><arg name="pmc"><space/>3164945<space/></arg><arg name="doi"><space/>10.1021/ja207142h<space/></arg></template></extension></paragraph><paragraph>A new class of antibiotics,<space/><link><target>Linezolid</target><part>oxazolidinones</part></link>, became available in the 1990s, and the first commercially available oxazolidinone,<space/><link><target>linezolid</target></link>, is comparable to vancomycin in effectiveness against MRSA. Linezolid-resistance in<space/><italics>S. aureus</italics><space/>was reported in 2001.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ<space/></arg><arg name="title"><space/>Linezolid resistance in a clinical isolate of Staphylococcus aureus<space/></arg><arg name="journal"><space/>The Lancet<space/></arg><arg name="volume"><space/>358<space/></arg><arg name="issue"><space/>9277<space/></arg><arg name="pages"><space/>207–208<space/></arg><arg name="pmid"><space/>11476839<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(01)05410-1<space/></arg><arg name="date">July 2001</arg></template></extension></paragraph><paragraph>Community-acquired MRSA (CA-MRSA) has now emerged as an epidemic that is responsible for rapidly progressive, fatal diseases, including necrotizing pneumonia, severe<space/><link><target>sepsis</target></link>, and<space/><link><target>necrotizing fasciitis</target></link>.<extension extension_name='ref' name="pmid17146447"><template><target>cite journal</target><arg name="author"><space/>Boyle-Vavra S, Daum RS<space/></arg><arg name="title"><space/>Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin<space/></arg><arg name="journal"><space/>Lab. Invest.<space/></arg><arg name="volume"><space/>87<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>3–9<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17146447<space/></arg><arg name="doi"><space/>10.1038/labinvest.3700501<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="last2"><space/>Daum<space/></arg><arg name="first2"><space/>RS<space/></arg></template></extension><space/>MRSA is the most frequently identified antimicrobial drug-resistant pathogen in US hospitals. The<space/><link><target>epidemiology</target></link><space/>of infections caused by MRSA is rapidly changing. In the past 10&amp;nbsp;years,<template><target>when</target><arg name="date">October 2012</arg></template><space/>infections caused by this organism have emerged in the community. The two MRSA clones in the United States most closely associated with community outbreaks,<space/><link><target>USA400</target></link><space/>(MW2 strain, ST1 lineage) and<space/><link><target>USA300</target></link>, often contain<space/><link><target>Panton-Valentine leukocidin</target></link><space/>(PVL) genes and, more frequently, have been associated with skin and soft tissue infections. Outbreaks of CA-MRSA infections have been reported in correctional facilities, among athletic teams, among military recruits, in newborn nurseries, and among men that have sex with men. CA-MRSA infections now appear endemic in many urban regions and cause most CA-<italics>S. aureus</italics><space/>infections.<extension extension_name='ref' name="pmid17479885"><template><target>cite journal</target><arg name="author"><space/>Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG<space/></arg><arg name="title"><space/>Community-associated Methicillin-resistant Staphylococcus aureus Isolates and Healthcare-Associated Infections<space/></arg><arg name="journal"><space/>Emerging Infect. Dis.<space/></arg><arg name="volume"><space/>13<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>236–42<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17479885<space/></arg><arg name="pmc"><space/>2725868<space/></arg><arg name="doi"><space/>10.3201/eid1302.060781<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension></paragraph><heading level='4'><italics>Streptococcus</italics><space/>and<space/><italics>Enterococcus</italics></heading><paragraph><italics><link><target>Streptococcus pyogenes</target></link></italics><space/>(Group A<space/><italics>Streptococcus</italics>: GAS) infections can usually be treated with many different antibiotics. Early treatment may reduce the risk of death from invasive group A streptococcal disease. However, even the best medical care does not prevent death in every case. For those with very severe illness, supportive care in an intensive-care unit may be needed. For persons with necrotizing fasciitis, surgery often is needed to remove damaged tissue.<extension extension_name='ref'><template><target>cite web</target><arg name="author">CDCP<space/></arg><arg name="title">Group A Streptococcal (GAS) Disease (strep throat, necrotizing fasciitis, impetigo) – Frequently Asked Questions<space/></arg><arg name="url">http://www.cdc.gov/ncidod/dbmd/diseaseinfo/groupastreptococcal_g.htm<space/></arg><arg name="date">2005-10-11<space/></arg><arg name="publisher">Centers for Disease Control and Prevention<space/></arg><arg name="accessdate">2007-12-11</arg><arg name="ref">harv</arg><arg name="archiveurl"><space/>http://web.archive.org/web/20071219224215/http://www.cdc.gov/ncidod/dbmd/diseaseinfo/groupastreptococcal_g.htm</arg><arg name="archivedate"><space/>19 December 2007<space/></arg><arg name="deadurl"><space/>no</arg></template></extension><space/>Strains of<space/><italics>S. pyogenes</italics><space/>resistant to<space/><link><target>macrolide</target></link><space/>antibiotics have emerged; however, all strains remain uniformly susceptible to<space/><link><target>penicillin</target></link>.<extension extension_name='ref' name="pmid15109426"><template><target>cite journal</target><arg name="author"><space/>Albrich WC, Monnet DL, Harbarth S<space/></arg><arg name="title"><space/>Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes<space/></arg><arg name="journal"><space/>Emerging Infect. Dis.<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>514–7<space/></arg><arg name="year"><space/>2004<space/></arg><arg name="pmid"><space/>15109426<space/></arg><arg name="pmc"><space/>3322805<space/></arg><arg name="doi"><space/>10.3201/eid1003.030252<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="last3"><space/>Harbarth<space/></arg><arg name="last2"><space/>Monnet<space/></arg><arg name="first2"><space/>DL<space/></arg><arg name="first3"><space/>S<space/></arg></template></extension></paragraph><paragraph>Resistance of<space/><italics><link><target>Streptococcus pneumoniae</target></link></italics><space/>to penicillin and other beta-lactams is increasing worldwide. The major mechanism of resistance involves the introduction of mutations in genes encoding penicillin-binding proteins. Selective pressure is thought to play an important role, and use of beta-lactam antibiotics has been implicated as a risk factor for infection and colonization.<space/><italics>S. pneumoniae</italics><space/>is responsible for<space/><link><target>pneumonia</target></link>,<space/><link><target>bacteremia</target></link>,<space/><link><target>otitis media</target></link>,<space/><link><target>meningitis</target></link>,<space/><link><target>sinusitis</target></link>,<space/><link><target>peritonitis</target></link><space/>and<space/><link><target>arthritis</target></link>.<extension extension_name='ref' name="pmid15109426"></extension></paragraph><paragraph>Multidrug-resistant<space/><italics><link><target>Enterococcus faecalis</target></link></italics><space/>and<space/><italics><link><target>Enterococcus faecium</target></link></italics><space/>are associated with<space/><link><target>nosocomial infection</target><trail>s</trail></link>.<extension extension_name='ref' name="pmid18947320"><template><target>cite journal</target><arg name="author"><space/>Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK<space/></arg><arg name="title"><space/>NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007<space/></arg><arg name="journal"><space/>Infect Control Hosp Epidemiol<space/></arg><arg name="volume"><space/>29<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>996–1011<space/></arg><arg name="date"><space/>November 2008<space/></arg><arg name="pmid"><space/>18947320<space/></arg><arg name="doi"><space/>10.1086/591861<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="author8"><space/>National Healthcare Safety Network Team<space/></arg><arg name="author9"><space/>Participating National Healthcare Safety Network Facilities<space/></arg></template></extension><space/>Among these strains,<space/><link><target>penicillin</target></link>-resistant<space/><italics><link><target>Enterococcus</target></link></italics><space/>was seen in 1983,<space/><link><target>vancomycin-resistant Enterococcus</target><part>vancomycin-resistant ''Enterococcus''</part></link><space/>in 1987, and<space/><link><target>linezolid</target></link>-resistant<space/><italics><link><target>Enterococcus</target></link></italics><space/>in the late 1990s.<template><target>Citation needed</target><arg name="date">April 2010</arg></template></paragraph><heading level='4'><italics>Pseudomonas aeruginosa</italics></heading><paragraph><italics><link><target>Pseudomonas aeruginosa</target></link></italics><space/>is a highly prevalent<space/><link><target>opportunistic pathogen</target></link>. One of the most worrisome characteristics of<space/><italics>P. aeruginosa</italics><space/>is its low antibiotic susceptibility, which is attributable to a concerted action of<space/><link><target>efflux (microbiology)</target><part>multidrug efflux pumps</part></link><space/>with chromosomally encoded antibiotic resistance genes (e.g.,<space/><italics>mexAB-oprM</italics>,<space/><italics>mexXY</italics>) and the low permeability of the bacterial cellular envelopes.<extension extension_name='ref' name="Poole2004"><template><target>cite journal</target><arg name="author"><space/>Poole K<space/></arg><arg name="title"><space/>Efflux-mediated multiresistance in Gram-negative bacteria<space/></arg><arg name="journal"><space/>Clinical Microbiology and Infection<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>12–26<space/></arg><arg name="year"><space/>2004<space/></arg><arg name="pmid"><space/>14706082<space/></arg><arg name="doi"><space/>10.1111/j.1469-0691.2004.00763.x<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension><space/><italics>Pseudomonas aeruginosa</italics><space/>has the ability to produce 4-hydroxy-2-alkylquinolines (HAQs) and it has been found that HAQs have prooxidant effects, and overexpressing modestly increased susceptibility to antibiotics. The study experimented with the<space/><italics>Pseudomonas aeruginosa</italics><space/>biofilms and found that a disruption of relA and spoT genes produced an inactivation of the Stringent response (SR) in cells with nutrient limitation, which provides cells be more susceptible to antibiotics.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, McKay G, Siehnel R, Schafhauser J, Wang Y, Britigan BE, Singh PK<space/></arg><arg name="title"><space/>Active Starvation Responses Mediate Antibiotic Tolerance in Biofilms and Nutrient-Limited Bacteria<space/></arg><arg name="journal"><space/>Science<space/></arg><arg name="volume"><space/>334<space/></arg><arg name="issue"><space/>6058<space/></arg><arg name="pages"><space/>982–6<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="pmid"><space/>22096200<space/></arg><arg name="doi"><space/>10.1126/science.1211037<space/></arg><arg name="bibcode"><space/>2011Sci...334..982N<space/></arg></template></extension></paragraph><heading level='4'><italics>Clostridium difficile</italics></heading><paragraph><italics><link><target>Clostridium difficile</target></link></italics><space/>is a nosocomial pathogen that causes diarrheal disease in hospitals world wide.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J<space/></arg><arg name="title"><space/>Clostridium difficile-associated diarrhea and colitis<space/></arg><arg name="journal"><space/>Infect. Control. Hosp. Epidemiol.<space/></arg><arg name="volume"><space/>16<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>459–477<space/></arg><arg name="year"><space/>1995<space/></arg><arg name="pmid"><space/>7594392<space/></arg><arg name="doi"><space/>10.1086/648363<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension><extension extension_name='ref' name="McDonald_2005"><template><target>cite journal</target><arg name="author"><space/>McDonald LC<space/></arg><arg name="title"><space/>''Clostridium difficile'': responding to a new threat from an old enemy<space/></arg><arg name="journal"><space/>Infect. Control. Hosp. Epidemiol.<space/></arg><arg name="volume"><space/>26<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>672–5<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>16156321<space/></arg><arg name="doi"><space/>10.1086/502600<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension></paragraph><paragraph><italics>C. difficile</italics><space/>colitis is most strongly associated with<space/><link><target>fluoroquinolones</target></link>,<space/><link><target>cephalosporins</target></link>,<space/><link><target>carbapenems</target></link>, and<space/><link><target>clindamycin</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Baxter R, Ray GT, Fireman BH<space/></arg><arg name="title"><space/>Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients<space/></arg><arg name="journal"><space/>Infection Control and Hospital Epidemiology : The Official Journal of the Society of Hospital Epidemiologists of America<space/></arg><arg name="volume"><space/>29<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>44–50<space/></arg><arg name="date"><space/>January 2008<space/></arg><arg name="pmid"><space/>18171186<space/></arg><arg name="doi"><space/>10.1086/524320<space/></arg></template></extension><extension extension_name='ref' name="pmid17072575"><template><target>cite journal</target><arg name="author"><space/>Gifford AH, Kirkland KB<space/></arg><arg name="title"><space/>Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward<space/></arg><arg name="journal"><space/>European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology<space/></arg><arg name="volume"><space/>25<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>751–5<space/></arg><arg name="date"><space/>December 2006<space/></arg><arg name="pmid"><space/>17072575<space/></arg><arg name="doi"><space/>10.1007/s10096-006-0220-1<space/></arg></template></extension><extension extension_name='ref' name="pmid16156323"><template><target>cite journal</target><arg name="author"><space/>Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA<space/></arg><arg name="title"><space/>Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital<space/></arg><arg name="journal"><space/>Infection Control and Hospital Epidemiology : The Official Journal of the Society of Hospital Epidemiologists of America<space/></arg><arg name="volume"><space/>26<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>680–4<space/></arg><arg name="date"><space/>August 2005<space/></arg><arg name="pmid"><space/>16156323<space/></arg><arg name="doi"><space/>10.1086/502602<space/></arg></template></extension></paragraph><paragraph>Some research suggests the overuse of antibiotics in the raising of livestock is contributing to outbreaks of bacterial infections such as C. difficile.[16]</paragraph><paragraph>Antibiotics, especially those with a broad activity spectrum (such as clindamycin) disrupt normal intestinal flora. This can lead to an overgrowth of C. difficile, which flourishes under these conditions. Pseudomembranous colitis can follow, creating generalized inflammation of the colon and the development of &quot;pseudomembrane&quot;, a viscous collection of inflammatory cells, fibrin, and necrotic cells.[4]<space/><link><target>Clindamycin</target></link>-resistant<space/><italics>C. difficile</italics><space/>was reported as the causative agent of large outbreaks of diarrheal disease in hospitals in New York, Arizona, Florida and Massachusetts between 1989 and 1992.<extension extension_name='ref' name="Johnson1999"><template><target>cite journal</target><arg name="author"><space/>Johnson S, Samore MH, Farrow KA, Killgore GE, Tenover FC, Lyras D, Rood JI, DeGirolami P, Baltch AL, Rafferty ME, Pear SM, Gerding DN<space/></arg><arg name="title"><space/>Epidemics of diarrhea caused by a clindamycin-resistant strain of ''Clostridium difficile'' in four hospitals<space/></arg><arg name="journal"><space/>New England Journal of Medicine<space/></arg><arg name="volume"><space/>341<space/></arg><arg name="issue"><space/>23<space/></arg><arg name="pages"><space/>1645–1651<space/></arg><arg name="year"><space/>1999<space/></arg><arg name="pmid"><space/>10572152<space/></arg><arg name="doi"><space/>10.1056/NEJM199911253412203<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension><space/>Geographically dispersed outbreaks of<space/><italics>C. difficile</italics><space/>strains resistant to<space/><link><target>fluoroquinolone</target></link><space/>antibiotics, such as ciprofloxacin and levofloxacin, were also reported in North America in 2005.<extension extension_name='ref' name="Loo_2005"><template><target>cite journal</target><arg name="author"><space/>Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A<space/></arg><arg name="title"><space/>A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality<space/></arg><arg name="journal"><space/>N Engl J Med<space/></arg><arg name="volume"><space/>353<space/></arg><arg name="issue"><space/>23<space/></arg><arg name="pages"><space/>2442–9<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>16322602<space/></arg><arg name="doi"><space/>10.1056/NEJMoa051639<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension></paragraph><heading level='4'><italics>Salmonella</italics><space/>and<space/><italics>E. coli</italics></heading><paragraph>Infection with<space/><italics><link><target>Escherichia coli</target></link></italics><space/>and<space/><italics><link><target>Salmonella</target></link></italics><space/>can result from the consumption of contaminated food and water. Both of these bacteria are well known for causing nosocomial (hospital-linked) infections, and often, these strains found in hospitals are antibiotic resistant due to adaptations to wide spread antibiotic use.<extension extension_name='ref' name="Davies2010"><template><target>cite journal</target><arg name="author"><space/>Davies J, Davies D<space/></arg><arg name="title"><space/>Origins and Evolution of Antibiotic Resistance<space/></arg><arg name="journal"><space/>Microbiol Mol Biol Rev<space/></arg><arg name="volume"><space/>74<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>417–433<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>20805405<space/></arg><arg name="doi"><space/>10.1128/MMBR.00016-10<space/></arg><arg name="ref"><space/>harv<space/></arg></template></extension><space/>When both bacteria are spread, serious health conditions arise. Many people are hospitalized each year after becoming infected, with some dying as a result. Since 1993, some strains of<space/><italics>E. coli</italics><space/>have become resistant to multiple types of<space/><link><target>quinolones</target><part>fluoroquinolone antibiotics</part></link>.<template><target>Citation needed</target><arg name="date">November 2011</arg></template></paragraph><paragraph>Although mutation alone plays a huge role in the development of antibiotic resistance, a 2008 study found that high survival rates after exposure to antibiotics could not be accounted for by mutation alone.<extension extension_name='ref' name="Adam2008"><template><target>cite journal</target><arg name="author"><space/>Adam M, Murali B, Glenn N, Potter S<space/></arg><arg name="title"><space/>Epigenetic inheritance based evolution of antibiotic resistance in bacteria<space/></arg><arg name="journal"><space/>BMC Evol<space/></arg><arg name="volume"><space/>8<space/></arg><arg name="pages"><space/>1–12<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="doi">10.1186/1471-2148-8-52</arg></template></extension><space/>This study focused on the development of resistance in E. coli to three antibiotic drugs: ampicillin, tetracycline, and nalidixic acid. The researchers found that some antibiotic resistance in E. coli developed due to epigenetic inheritance rather than by direct inheritance of a mutated gene. This was further supported by data showing that reversion to antibiotic sensitivity was relatively common as well. This could only be explained by epigenetics.<extension extension_name='ref' name="Adam2008"></extension><space/>Epigenetics is a type of inheritance in which gene expression is altered rather than the genetic code itself. There are many modes by which this alteration of gene expression can occur, including methylation of DNA and histone modification; however, the important point is that both inheritance of random mutations and epigenetic markers can result in the expression of antibiotic resistance genes.<extension extension_name='ref' name="Adam2008"></extension></paragraph><heading level='4'><italics>Acinetobacter baumannii</italics></heading><paragraph>On November 5, 2004, the<space/><link><target>Centers for Disease Control and Prevention</target></link><space/>(CDC) reported an increasing number of<space/><italics><link><target>Acinetobacter baumannii</target></link></italics><space/>bloodstream infections in patients at military medical facilities in which service members injured in the<space/><link><target>Iraq</target></link>/<link><target>Kuwait</target></link><space/>region during<space/><link><target>Iraq war</target><part>Operation Iraqi Freedom</part></link><space/>and in<space/><link><target>Afghanistan</target></link><space/>during<space/><link><target>Operation Enduring Freedom</target></link><space/>were treated. Most of these showed<space/><link><target>multidrug resistance</target></link><space/>(MRAB), with a few isolates resistant to all drugs tested.<extension extension_name='ref' name="pmid15549020"><template><target>cite journal</target><arg name="author"><space/></arg><arg name="title"><space/>Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002–2004<space/></arg><arg name="journal"><space/>MMWR Morb. Mortal. Wkly. Rep.<space/></arg><arg name="volume"><space/>53<space/></arg><arg name="issue"><space/>45<space/></arg><arg name="pages"><space/>1063–6<space/></arg><arg name="year"><space/>2004<space/></arg><arg name="pmid"><space/>15549020<space/></arg><arg name="url"><space/>http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5345a1.htm<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="publisher"><space/>Centers for Disease Control and Prevention (CDC)<space/></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.medscape.com/viewarticle/575837<space/></arg><arg name="title">Medscape abstract on Acinetobacter baumannii: Acinetobacter baumannii: An Emerging Multidrug-resistant Threat</arg><arg name="ref">harv</arg><arg name="quote">membership only website</arg></template></extension></paragraph><heading level='4'><italics>Klebsiella pneumoniae</italics></heading><paragraph>Klebsiella pneumoniae carbapenemase (<link><target>Beta-lactamase#KPC (K. pneumoniae carbapenemase) (Class A)</target><part>KPC</part></link>)-producing bacteria are a group of emerging highly drug-resistant Gram-negative bacilli causing infections associated with significant morbidity and mortality whose incidence is rapidly increasing in a variety of clinical settings around the world.<space/><italics>Klebsiella pneumoniae</italics><space/>includes numerous mechanisms for antibiotic resistance, many of which are located on highly mobile genetic elements.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Hudson</arg><arg name="first1">Corey</arg><arg name="last2">Bent</arg><arg name="first2">Zachary</arg><arg name="last3">Meagher</arg><arg name="first3">Robert</arg><arg name="last4">Williams</arg><arg name="first4">Kelly</arg><arg name="title">Resistance Determinants and Mobile Genetic Elements of an NDM-1-Encoding Klebsiella pneumoniae Strain</arg><arg name="journal">PLoS ONE</arg><arg name="date">June 7, 2014</arg><arg name="doi">10.1371/journal.pone.0099209</arg><arg name="url">http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0099209</arg><arg name="pmid">24905728</arg><arg name="volume">9</arg><arg name="pages">e99209</arg></template></extension><space/><link><target>Carbapenem</target></link><space/>antibiotics (heretofore often the treatment of last resort for resistant infections) are generally not effective against KPC-producing organisms.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Arnold RS, Thom KA, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ<space/></arg><arg name="title"><space/>Emergence of Klebsiella pneumoniae Carbapenemase-Producing Bacteria<space/></arg><arg name="journal"><space/>Southern Medical Journal<space/></arg><arg name="volume"><space/>104<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>40–5<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="pmid"><space/>21119555<space/></arg><arg name="pmc"><space/>3075864<space/></arg><arg name="doi"><space/>10.1097/SMJ.0b013e3181fd7d5a<space/></arg></template></extension></paragraph><heading level='4'><italics>Mycobacterium tuberculosis</italics></heading><paragraph><link><target>Tuberculosis</target></link><space/>is increasing across the globe, especially in developing countries, over the past few years. TB resistant to antibiotics is called<space/><link><target>Multi-drug-resistant tuberculosis</target><part>MDR TB</part></link><space/>(Multidrug Resistant TB). Globally, MDR TB causes 150,000 deaths annually.<extension extension_name='ref'><template><target>cite web</target><arg name="publisher">Agency for Healthcare Research and Quality<space/></arg><arg name="url">https://innovations.ahrq.gov/perspectives/antimicrobial-resistance-still-poses-public-health-threat<space/></arg><arg name="title">Antimicrobial Resistance Still Poses a Public Health Threat: A Conversation With Edward J. Septimus, MD, FIDSA, FACP, FSHEA, Clinical Professor of Internal Medicine at Texas A&M Health Science Center<space/></arg><arg name="date">2013-04-17<space/></arg><arg name="accessdate">2013-09-26</arg></template></extension><space/>The rise of the HIV/AIDS epidemic has contributed to this.<extension extension_name='ref' name="journals.lww.com"><template><target>cite journal</target><arg name="author"><space/>LoBue P<space/></arg><arg name="title"><space/>Extensively drug-resistant tuberculosis<space/></arg><arg name="journal"><space/>Current Opinion in Infectious Diseases<space/></arg><arg name="volume"><space/>22<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>167–73<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19283912<space/></arg><arg name="doi"><space/>10.1097/QCO.0b013e3283229fab<space/></arg></template></extension></paragraph><paragraph>TB was considered one of the most prevalent diseases, and did not have a cure until the discovery of<space/><link><target>Streptomycin</target></link><space/>by<space/><link><target>Selman Waksman</target></link><space/>in 1943.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Herzog H<space/></arg><arg name="title"><space/>History of Tuberculosis<space/></arg><arg name="journal"><space/>Respiration<space/></arg><arg name="volume"><space/>65<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>5–15<space/></arg><arg name="year"><space/>1998<space/></arg><arg name="pmid"><space/>9523361<space/></arg><arg name="doi"><space/>10.1159/000029220<space/></arg></template></extension><space/>However, the bacteria soon developed resistance. Since then, drugs such as<space/><link><target>isoniazid</target></link><space/>and<space/><link><target>rifampin</target></link><space/>have been used. M. tuberculosis develops resistance to drugs by spontaneous mutations in its genomes. Resistance to one drug is common, and this is why treatment is usually done with more than one drug.<space/><link><target>Extensively drug-resistant tuberculosis</target><part>Extensively Drug-Resistant TB</part></link><space/>(XDR TB) is TB that is also resistant to the second line of drugs.<extension extension_name='ref' name="journals.lww.com"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1016/j.ddmec.2010.09.006<space/></arg><arg name="title">Transmission of MDR tuberculosis<space/></arg><arg name="year">2010<space/></arg><arg name="last1">Gao<space/></arg><arg name="first1">Qian<space/></arg><arg name="last2">Li<space/></arg><arg name="first2">Xia<space/></arg><arg name="journal">Drug Discovery Today: Disease Mechanisms<space/></arg><arg name="volume">7<space/></arg><arg name="pages">e61</arg></template></extension></paragraph><paragraph>Resistance of<space/><italics><link><target>Mycobacterium tuberculosis</target></link></italics><space/>to<space/><link><target>isoniazid</target></link>,<space/><link><target>rifampin</target></link>, and other common treatments has become an increasingly relevant clinical challenge. (For more on Drug-Resistant TB, visit the<space/><link><target>Multi-drug-resistant tuberculosis</target></link><space/>page.) Evidence is lacking for whether these bacteria have plasmids.<extension extension_name='ref' name="pmid2115217"><template><target>cite journal</target><arg name="author"><space/>Zainuddin ZF, Dale JW<space/></arg><arg name="title"><space/>Does Mycobacterium tuberculosis have plasmids?<space/></arg><arg name="journal"><space/>Tubercle<space/></arg><arg name="volume"><space/>71<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>43–9<space/></arg><arg name="year"><space/>1990<space/></arg><arg name="pmid"><space/>2115217<space/></arg><arg name="doi"><space/>10.1016/0041-3879(90)90060-l<space/></arg></template></extension><space/>Also<space/><italics>M. tuberculosis</italics><space/>lack the opportunity to interact with other bacteria in order to share plasmids.<extension extension_name='ref' name="pmid2115217"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PD, Victor TC<space/></arg><arg name="title"><space/>A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance<space/></arg><arg name="journal"><space/>Antimicrobial Agents and Chemotherapy<space/></arg><arg name="volume"><space/>53<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>3181–9<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19451293<space/></arg><arg name="pmc"><space/>2715638<space/></arg><arg name="doi"><space/>10.1128/AAC.01577-08<space/></arg></template></extension></paragraph><heading level='4'><italics>Neisseria gonorrhoeae</italics></heading><paragraph><template><target>main</target><arg>Antibiotic resistance in gonorrhea</arg></template><link><target>Neisseria gonorrhoeae</target></link><space/>is a sexually transmitted pathogen that can cause pelvic pain, pain on urination, penile and vaginal discharge, as well as systemic symptoms. The bacteria was first identified in 1879,<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Ligon</arg><arg name="first">B. Lee</arg><arg name="title">Albert Ludwig Sigesmund Neisser: Discoverer of the Cause of Gonorrhea</arg><arg name="journal">Seminars in Pediatric Infectious Diseases</arg><arg name="date">October 2005</arg><arg name="volume">16</arg><arg name="issue">4</arg><arg name="pages">336–341</arg><arg></arg><arg name="doi">10.1053/j.spid.2005.07.001</arg></template></extension><space/>although some Biblical scholars believe that references to the disease can be found as early as Parshat Metzora of the<space/><link><target>Old Testament</target></link>.<extension extension_name='ref'><template><target>cite book</target><arg name="last">Rosner</arg><arg name="first">Fred</arg><arg name="title">Medicine in the Bible and the Talmud : selections from classical Jewish sources</arg><arg name="year">1995</arg><arg name="publisher">KTAV Pub. House</arg><arg name="location">Hoboken, NJ</arg><arg name="isbn">0-88125-506-8</arg><arg name="edition">Augm.</arg></template></extension></paragraph><paragraph>In the 1940s effective treatment with<space/><link><target>penicillin</target></link><space/>became available, but by the 1970s resistant strains predominated. Resistance to penicillin has developed through two mechanisms: chomasomally mediated resistance (CMRNG) and penicillinase-mediated resistance (PPNG). CMRNG involves stepwise mutation of penA, which codes for the penicilin-binding protein (PBP-2); mtr, which encodes an efflux pump to remove penicilin from the cell; and penB, which encodes the bacterial cell wall porins. PPNG involves the acquisition of a plasmid-borne beta-lactamase.<extension extension_name='ref' name="Tapsall 2001">Tapsall (2001) Antimicrobial resistance in<space/><italics>Niesseria gonorrhoeae</italics>. World Health Organization.</extension></paragraph><paragraph><link><target>quinolones</target><part>Fluoroquinolones</part></link><space/>were a useful next-line treatment until resistance was achieved through efflux pumps and mutations to the gyrA gene, which encodes<space/><link><target>DNA gyrase</target></link>.<extension extension_name='ref' name="Tapsall 2001"></extension><space/>Third-generation<space/><link><target>cephalosporins</target></link><space/>have been used to treat gonorrhoea since 2007, but resistant strains have emerged. Strains of Neisseria gonorrhoea have also been found to be resistant to<space/><link><target>tetracyclines</target></link><space/>and<space/><link><target>aminoglycosides</target></link>. Neisseria gonorrheoea has a high affinity for horizontal gene transfer, and as a result, the existence of any strain resistant to a given drug could spread easily across strains.</paragraph><paragraph>As of 2010, the recommended treatment is a single 250&amp;nbsp;mg intramuscular injection of<space/><link><target>ceftriaxone</target></link>, sometimes in combination with<space/><link><target>azithromycin</target></link><space/>or<space/><link><target>doxycycline</target></link>.<extension extension_name='ref' name="Japan10"><template><target>cite journal</target><arg name="author"><space/>Deguchi T, Nakane K, Yasuda M, Maeda S<space/></arg><arg name="title"><space/>Emergence and spread of drug resistant Neisseria gonorrhoeae<space/></arg><arg name="journal"><space/>J. Urol.<space/></arg><arg name="volume"><space/>184<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>851–8; quiz 1235<space/></arg><arg name="date"><space/>September 2010<space/></arg><arg name="pmid"><space/>20643433<space/></arg><arg name="doi"><space/>10.1016/j.juro.2010.04.078<space/></arg><arg name="url"><space/></arg></template></extension><extension extension_name='ref' name="MMWR2012"><template><target>cite journal</target><arg name="author"><space/></arg><arg name="title"><space/>Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections.<space/></arg><arg name="journal"><space/>MMWR. Morbidity and mortality weekly report<space/></arg><arg name="volume"><space/>61<space/></arg><arg name="issue"><space/>31<space/></arg><arg name="pages"><space/>590–4<space/></arg><arg name="date"><space/>Aug 10, 2012<space/></arg><arg name="pmid"><space/>22874837<space/></arg></template></extension></paragraph><heading level='3'>Viruses</heading><paragraph>Specific<space/><link><target>antiviral drug</target><trail>s</trail></link><space/>are used to treat some viral infections. These drugs prevent viruses from reproducing by inhibiting essential stages of the virus's replication cycle in infected cells. Antivirals are used to treat<space/><link><target>HIV</target></link>,<space/><link><target>hepatitis B</target></link>,<space/><link><target>hepatitis C</target></link>,<space/><link><target>influenza</target></link>,<space/><link><target>herpesviridae</target><part>herpes viruses</part></link><space/>including<space/><link><target>varicella zoster virus</target></link>,<space/><link><target>cytomegalovirus</target></link><space/>and<space/><link><target>Epstein-Barr virus</target></link>. With each virus, some strains have become resistant to the administered drugs.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Lou</arg><arg name="first1">Z</arg><arg name="last2">Sun</arg><arg name="first2">Y</arg><arg name="last3">Rao</arg><arg name="first3">Z</arg><arg name="title">Current progress in antiviral strategies.</arg><arg name="journal">Trends in pharmacological sciences</arg><arg name="date">February 2014</arg><arg name="volume">35</arg><arg name="issue">2</arg><arg name="pages">86–102</arg><arg name="pmid">24439476</arg><arg name="doi">10.1016/j.tips.2013.11.006</arg></template></extension></paragraph><paragraph>Resistance to HIV antivirals is problematic, and even multi-drug resistant strains have evolved.<extension extension_name='ref'><template><target>Cite journal</target><arg name="pmid"><space/>24470969</arg><arg name="pmc"><space/>3892620</arg><arg name="year"><space/>2013</arg><arg name="author1"><space/>Pennings</arg><arg name="first1"><space/>P. S.</arg><arg name="title"><space/>HIV Drug Resistance: Problems and Perspectives</arg><arg name="journal"><space/>Infectious Disease Reports</arg><arg name="volume"><space/>5</arg><arg name="issue"><space/>Suppl 1</arg><arg name="pages"><space/>e5</arg><arg name="doi"><space/>10.4081/idr.2013.s1.e5</arg></template></extension><space/>Resistant strains of the HIV virus emerge rapidly if only one antiviral drug is used.<extension extension_name='ref'><template><target>Cite journal</target><arg name="pmid"><space/>23432488</arg><arg name="year"><space/>2013</arg><arg name="author1"><space/>Ton</arg><arg name="first1"><space/>Q</arg><arg name="title"><space/>HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission</arg><arg name="journal"><space/>Current HIV research</arg><arg name="volume"><space/>11</arg><arg name="issue"><space/>2</arg><arg name="pages"><space/>126–36</arg><arg name="last2"><space/>Frenkel</arg><arg name="first2"><space/>L</arg><arg name="doi">10.2174/1570162x11311020005</arg></template></extension><space/>Using three or more drugs together has helped to control this problem, but new drugs are needed because of the continuing emergence of drug-resistant HIV strains.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Ebrahim</arg><arg name="first1">O</arg><arg name="last2">Mazanderani</arg><arg name="first2">AH</arg><arg name="title">Recent developments in hiv treatment and their dissemination in poor countries.</arg><arg name="journal">Infectious disease reports</arg><arg name="date">6 June 2013</arg><arg name="volume">5</arg><arg name="issue">Suppl 1</arg><arg name="pages">e2</arg><arg name="pmid">24470966</arg></template></extension></paragraph><heading level='3'>Fungi</heading><paragraph>Infections by fungi are a cause of high morbidity and mortality in immunocompromised persons, such as those with HIV/AIDS, tuberculosis or receiving<space/><link><target>chemotherapy</target></link>.<extension extension_name='ref'><template><target>Cite journal</target><arg name="pmid"><space/>24810351</arg><arg name="year"><space/>2014</arg><arg name="author1"><space/>Xie</arg><arg name="first1"><space/>J. L.</arg><arg name="title"><space/>Elucidating drug resistance in human fungal pathogens</arg><arg name="journal"><space/>Future Microbiology</arg><arg name="volume"><space/>9</arg><arg name="issue"><space/>4</arg><arg name="pages"><space/>523–42</arg><arg name="last2"><space/>Polvi</arg><arg name="first2"><space/>E. J.</arg><arg name="last3"><space/>Shekhar-Guturja</arg><arg name="first3"><space/>T</arg><arg name="last4"><space/>Cowen</arg><arg name="first4"><space/>L. E.</arg><arg name="doi"><space/>10.2217/fmb.14.18</arg></template></extension><space/>The fungi<space/><link><target>Candida (fungus)</target><part>candida</part></link>,<space/><link><target>Cryptococcus neoformans</target></link><space/>and<space/><link><target>Aspergillus fumigatus</target></link><space/>cause most of these infections and antifungal resistance occurs in all of them.<extension extension_name='ref'><template><target>Cite journal</target><arg name="pmid"><space/>24847655</arg><arg name="pmc"><space/>4031462</arg><arg name="year"><space/>2014</arg><arg name="author1"><space/>Srinivasan</arg><arg name="first1"><space/>A</arg><arg name="title"><space/>Overcoming antifungal resistance</arg><arg name="journal"><space/>Drug Discovery Today: Technologies</arg><arg name="volume"><space/>11</arg><arg name="pages"><space/>65–71</arg><arg name="last2"><space/>Lopez-Ribot</arg><arg name="first2"><space/>J. L.</arg><arg name="last3"><space/>Ramasubramanian</arg><arg name="first3"><space/>A. K.</arg><arg name="doi"><space/>10.1016/j.ddtec.2014.02.005</arg></template></extension><space/>Multidrug resistance in fungi is increasing because of the widespread use of antifungal drugs to treat infections in immunocompromised individuals.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Costa</arg><arg name="first1">C</arg><arg name="last2">Dias</arg><arg name="first2">PJ</arg><arg name="last3">Sá-Correia</arg><arg name="first3">I</arg><arg name="last4">Teixeira</arg><arg name="first4">MC</arg><arg name="title">MFS multidrug transporters in pathogenic fungi: do they have real clinical impact?</arg><arg name="journal">Frontiers in physiology</arg><arg name="date">2014</arg><arg name="volume">5</arg><arg name="pages">197</arg><arg name="pmid">24904431</arg><arg name="doi">10.3389/fphys.2014.00197</arg></template></extension></paragraph><heading level='3'>Parasites</heading><paragraph>The<space/><link><target>protozoa</target><trail>n</trail></link><space/>parasites that cause the diseases<space/><link><target>malaria</target></link>,<space/><link><target>trypanosomiasis</target></link>,<space/><link><target>toxoplasmosis</target></link>,<space/><link><target>cryptosporidiosis</target></link><space/>and<space/><link><target>leishmaniasis</target></link><space/>are important human pathogens.<extension extension_name='ref' name="pmid25057459"><template><target>Cite journal</target><arg name="pmid"><space/>25057459</arg><arg name="pmc"><space/>4095053</arg><arg name="year"><space/>2014</arg><arg name="author1"><space/>Andrews</arg><arg name="first1"><space/>K. T.</arg><arg name="title"><space/>Drug repurposing and human parasitic protozoan diseases</arg><arg name="journal"><space/>International Journal for Parasitology: Drugs and Drug Resistance</arg><arg name="volume"><space/>4</arg><arg name="issue"><space/>2</arg><arg name="pages"><space/>95-111</arg><arg name="last2"><space/>Fisher</arg><arg name="first2"><space/>G</arg><arg name="last3"><space/>Skinner-Adams</arg><arg name="first3"><space/>T. S.</arg><arg name="doi"><space/>10.1016/j.ijpddr.2014.02.002</arg></template></extension></paragraph><paragraph>Malarial parasites that are resistant to the drugs that are currently available to infections are common and this has led to increased efforts to develop new drugs.<extension extension_name='ref'><template><target>Cite journal</target><arg name="pmid"><space/>25110058</arg><arg name="year"><space/>2014</arg><arg name="author1"><space/>Visser</arg><arg name="first1"><space/>B. J.</arg><arg name="title"><space/>Malaria: An update on current chemotherapy</arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy</arg><arg name="volume"><space/>15</arg><arg name="issue"><space/>15</arg><arg name="pages"><space/>2219–54</arg><arg name="last2"><space/>Van Vugt</arg><arg name="first2"><space/>M</arg><arg name="last3"><space/>Grobusch</arg><arg name="first3"><space/>M. P.</arg><arg name="doi"><space/>10.1517/14656566.2014.944499</arg></template></extension><space/>Resistance to recently developed drugs such as<space/><link><target>artemisinin</target></link><space/>has also been reported. The problem of drug resistance in malaria has driven efforts to develop vaccines.<extension extension_name='ref'><template><target>Cite journal</target><arg name="pmid"><space/>25452745</arg><arg name="pmc"><space/>4233905</arg><arg name="year"><space/>2014</arg><arg name="author1"><space/>Chia</arg><arg name="first1"><space/>W. N.</arg><arg name="title"><space/>Novel approaches to identify protective malaria vaccine candidates</arg><arg name="journal"><space/>Frontiers in Microbiology</arg><arg name="volume"><space/>5</arg><arg name="pages"><space/>586</arg><arg name="last2"><space/>Goh</arg><arg name="first2"><space/>Y. S.</arg><arg name="last3"><space/>Rénia</arg><arg name="first3"><space/>L</arg><arg name="doi"><space/>10.3389/fmicb.2014.00586</arg></template></extension></paragraph><paragraph><link><target>Trypanosoma</target><part>Trypanosome</part><trail>s</trail></link><space/>are parasitic protozoa that cause<space/><link><target>African trypanosomiasis</target></link><space/>and<space/><link><target>Chagas disease</target></link><space/>(American trypanosomiasis).<extension extension_name='ref'><template><target>Cite journal</target><arg name="pmid"><space/>25125985</arg><arg name="pmc"><space/>4130665</arg><arg name="year"><space/>2014</arg><arg name="author1"><space/>Franco</arg><arg name="first1"><space/>J. R.</arg><arg name="title"><space/>Epidemiology of human African trypanosomiasis</arg><arg name="journal"><space/>Clinical Epidemiology</arg><arg name="volume"><space/>6</arg><arg name="pages"><space/>257–75</arg><arg name="last2"><space/>Simarro</arg><arg name="first2"><space/>P. P.</arg><arg name="last3"><space/>Diarra</arg><arg name="first3"><space/>A</arg><arg name="last4"><space/>Jannin</arg><arg name="first4"><space/>J. G.</arg><arg name="doi"><space/>10.2147/CLEP.S39728</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Herrera</arg><arg name="first1">L</arg><arg name="title">Trypanosoma cruzi, the Causal Agent of Chagas Disease: Boundaries between Wild and Domestic Cycles in Venezuela.</arg><arg name="journal">Frontiers in public health</arg><arg name="date">2014</arg><arg name="volume">2</arg><arg name="pages">259</arg><arg name="pmid">25506587</arg><arg name="doi">10.3389/fpubh.2014.00259</arg></template></extension><space/>There are no vaccines to prevent these infections so drugs such as<space/><link><target>pentamidine</target></link><space/>and<space/><link><target>suramin</target></link>,<space/><link><target>benznidazole</target></link><space/>and<space/><link><target>nifurtimox</target></link><space/>and used to treat infections. These drugs are effective but infections caused by resistant parasites have been reported.<extension extension_name='ref' name="pmid25057459"></extension></paragraph><paragraph><link><target>Leishmaniasis</target></link><space/>is caused by protozoa and is an important public health problem worldwide, especially in sub-tropical and tropical countries. Drug resistance has &quot;become a major concern&quot;.<extension extension_name='ref'><template><target>Cite journal</target><arg name="pmid"><space/>25287721</arg><arg name="year"><space/>2014</arg><arg name="author1"><space/>Mansueto</arg><arg name="first1"><space/>P</arg><arg name="title"><space/>Leishmaniasis in travelers: A literature review</arg><arg name="journal"><space/>Travel Medicine and Infectious Disease</arg><arg name="volume"><space/>12</arg><arg name="issue"><space/>6PA</arg><arg name="pages"><space/>563–581</arg><arg name="last2"><space/>Seidita</arg><arg name="first2"><space/>A</arg><arg name="last3"><space/>Vitale</arg><arg name="first3"><space/>G</arg><arg name="last4"><space/>Cascio</arg><arg name="first4"><space/>A</arg><arg name="doi"><space/>10.1016/j.tmaid.2014.09.007</arg></template></extension></paragraph><heading level='2'>Applications</heading><paragraph><template><target>refimprove section</target><arg name="date">May 2015</arg></template>Antibiotic resistance is an important tool for<space/><link><target>genetic engineering</target></link>. By constructing a<space/><link><target>plasmid</target></link><space/>that contains an antibiotic-resistance gene as well as the gene being engineered or expressed, a researcher can ensure that, when bacteria replicate, only the copies that carry the plasmid survive. This ensures that the gene being manipulated passes along when the bacteria replicates.</paragraph><paragraph>In general, the most commonly used antibiotics in genetic engineering are &quot;older&quot; antibiotics. These include:</paragraph><list type='bullet'><listitem><link><target>ampicillin</target></link></listitem><listitem><link><target>kanamycin</target></link></listitem><listitem><link><target>tetracycline</target></link></listitem><listitem><link><target>chloramphenicol</target></link></listitem></list><paragraph>In industry, the use of antibiotic resistance is disfavored, since maintaining bacterial cultures would require feeding them large quantities of antibiotics. Instead, the use of<space/><link><target>auxotrophic</target></link><space/>bacterial strains (and function-replacement plasmids) is preferred.</paragraph><heading level='2'>Society and culture</heading><paragraph>For the<space/><link><target>fiscal year</target></link><space/>2016 budget, President Obama has suggested to nearly double the amount of federal funding to &quot;combat and prevent&quot; antibiotic resistance to more than $1.2 billion.<extension extension_name='ref'><link type='external' href='https://www.whitehouse.gov/the-press-office/2015/01/27/fact-sheet-president-s-2016-budget-proposes-historic-investment-combat-a'>Presidents 2016 Budget Proposes Historic Investment to Combat Antibiotic-Resistant Bacteria to Protect Public Health</link><space/>The White House, Office of the Press Secretary, January 27, 2015</extension></paragraph><heading level='3'>Legal frameworks</heading><paragraph>Some global health scholars have argued that a global, legal framework is needed to prevent and control antimicrobial resistance.<extension extension_name='ref'><preblock><preline>A. Behdinan, S.J. Hoffman. 2015. Some Global Strategies for Antibiotic Resistance Require Legally Binding and Enforceable Commitments, Journal of Law, Medicine &amp; Ethics 43(2).</preline></preblock></extension><extension extension_name='ref'><preblock><preline>S.J. Hoffman, T. Ottersen. 2015. Mounting An Effective Response to Antibiotic Resistance Requires a Robust Global Accountability Framework, Journal of Law, Medicine &amp; Ethics 43(2).</preline></preblock></extension><template><target>page needed</target><arg name="date">September 2015</arg></template><extension extension_name='ref'>Z. Rizvi, S.J. Hoffman. 2015. Effective Global Action on Antibiotic Resistance Calls for Careful Consideration of the Convening Forum, Journal of Law, Medicine &amp; Ethics 43(2).</extension><extension extension_name='ref' name="Hoffman">S.J. Hoffman, K. Outterson, J-A. Rttingen, O. Cars, C. Clift, Z. Rizvi, F. Rotberg, G. Tomson, A. Zorzet. An International Legal Framework to Address Antimicrobial Resistance, Bulletin of the World Health Organization 96(2): 66. doi:10.2471/BLT.15.152710</extension><template><target>page needed</target><arg name="date">September 2015</arg></template><space/>For instance, binding global policies could be used to create antimicrobial use standards, regulate antibiotic marketing, and strengthen global surveillance systems.<extension extension_name='ref' name="Hoffman"></extension><template><target>page needed</target><arg name="date">September 2015</arg></template><extension extension_name='ref'><preblock><preline>A. Behdinan, S.J. Hoffman. 2015. Some Global Strategies for Antibiotic Resistance Require Legally Binding and Enforceable Commitments, Journal of Law, Medicine &amp; Ethics 43(2).</preline></preblock></extension><template><target>page needed</target><arg name="date">September 2015</arg></template><space/>Ensuring compliance of involved parties is a challenge.<extension extension_name='ref' name="Hoffman"></extension><template><target>page needed</target><arg name="date">September 2015</arg></template><space/>Global antimicrobial resistance policies could take lessons from the environmental sector by adopting strategies that have made international environmental agreements successful in the past such as: sanctions for non-compliance, assistance for implementation, majority vote decision-making rules, an independent scientific panel, and specific commitments.<extension extension_name='ref'><preblock><preline>S. Andresen, S.J. Hoffman. 2015. Much Can Be Learned about Addressing Antibiotic Resistance from Multilateral Environmental Agreements Journal of Law, Medicine &amp; Ethics 43(2).</preline></preblock></extension><template><target>page needed</target><arg name="date">September 2015</arg></template></paragraph><heading level='2'>See also</heading><list type='bullet'><listitem><link><target>Alliance for the Prudent Use of Antibiotics</target></link></listitem><listitem><link><target>Antibacterial soap</target></link></listitem><listitem><link><target>Beta-lactamase#KPC (K. pneumoniae carbapenemase) (Class A)</target><part>(KPC) antibacterial resistance gene</part></link></listitem><listitem><link><target>Broad-spectrum antibiotic</target></link></listitem><listitem><link><target>Carbapenem resistant enterobacteriaceae</target></link></listitem><listitem><link><target>Colonisation resistance</target></link></listitem><listitem><link><target>Drug of last resort</target></link></listitem><listitem><link><target>Multidrug tolerance</target></link></listitem><listitem><link><target>Multidrug-resistant gram-negative bacteria</target></link></listitem><listitem><link><target>New Delhi metallo-beta-lactamase</target><part>(NDM-1) antibacterial resistance gene</part></link></listitem></list><heading level='2'>Footnotes</heading><paragraph><template><target>Reflist</target><arg>30em</arg></template></paragraph><heading level='2'>References</heading><list type='def'><listitem><defkey>Books</defkey></listitem></list><list type='bullet'><listitem><template><target>cite web</target><arg name="url">http://evolution.berkeley.edu/evolibrary/article/mutations_07</arg><arg name="trans_title"><space/>Mutations are random</arg><arg name="title">Understanding Evolution</arg><arg name="publisher">University of California Museum of Paleontology<space/></arg><arg name="editor-first">Roy<space/></arg><arg name="editor-last">Caldwell<space/></arg><arg name="editor2-first">David<space/></arg><arg name="editor2-last">Lindberg</arg><arg name="year">2011</arg><arg name="accessdate">Aug 14, 2011</arg><arg name="ref">harv</arg></template></listitem><listitem><template><target>cite book</target><arg name="first">Richard William<space/></arg><arg name="last"><space/>Nelson</arg><arg name="title">Darwin, Then and Now: The Most Amazing Story in the History of Science</arg><arg name="publisher"><space/>iUniverse</arg><arg name="year">2009</arg><arg name="page">294</arg><arg name="ref">harv</arg><arg name="type"><space/>Self Published</arg></template></listitem></list><list type='def'><listitem><defkey>Journals</defkey></listitem></list><list type='bullet'><listitem><template><target>cite journal</target><arg name="author"><space/>Arias CA, Murray BE<space/></arg><arg name="title"><space/>Antibiotic-Resistant Bugs in the 21st Century&nbsp;— A Clinical Super-Challenge<space/></arg><arg name="journal"><space/>[[New England Journal of Medicine]]<space/></arg><arg name="volume"><space/>360<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>439–443<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19179312<space/></arg><arg name="doi"><space/>10.1056/NEJMp0804651<space/></arg><arg name="url"><space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="last2"><space/>Murray<space/></arg><arg name="first2"><space/>BE<space/></arg><arg name="accessdate"><space/></arg></template></listitem><listitem><template><target>cite journal</target><arg name="author"><space/>Goossens H, Ferech M, Vander Stichele R, Elseviers M<space/></arg><arg name="title"><space/>Outpatient antibiotic use in Europe and association with resistance: a cross-national database study<space/></arg><arg name="journal"><space/>Lancet<space/></arg><arg name="volume"><space/>365<space/></arg><arg name="issue"><space/>9459<space/></arg><arg name="pages"><space/>579–87<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>15708101<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(05)17907-0<space/></arg><arg name="ref"><space/>harv<space/></arg><arg name="last5"><space/>Esac Project<space/></arg><arg name="series"><space/>Group Esac Project<space/></arg><arg name="last4"><space/>Elseviers<space/></arg><arg name="first5"><space/>Group<space/></arg><arg name="last3"><space/>Vander Stichele<space/></arg><arg name="last2"><space/>Ferech<space/></arg><arg name="first2"><space/>M<space/></arg><arg name="first3"><space/>R<space/></arg><arg name="first4"><space/>M<space/></arg></template></listitem><listitem><template><target>cite journal</target><arg name="last">Hawkey</arg><arg name="first">PM</arg><arg name="last2">Jones<space/></arg><arg name="first2">AM</arg><arg name="title">The changing epidemiology of resistance</arg><arg name="journal">The Journal of antimicrobial chemotherapy</arg><arg name="date">September 2009<space/></arg><arg name="volume">64 Suppl 1</arg><arg name="pages">i3–10</arg><arg name="pmid">19675017</arg><arg name="doi">10.1093/jac/dkp256</arg><arg name="ref">harv</arg></template></listitem><listitem><template><target>cite journal</target><arg name="author"><space/>Soulsby EJ<space/></arg><arg name="title"><space/>Resistance to antimicrobials in humans and animals: Overusing antibiotics is not the only cause and reducing use is not the only solution<space/></arg><arg name="journal"><space/>[[British Medical Journal]]<space/></arg><arg name="volume"><space/>331<space/></arg><arg name="issue"><space/>7527<space/></arg><arg name="pages"><space/>1219–20<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>16308360<space/></arg><arg name="pmc"><space/>1289307<space/></arg><arg name="doi"><space/>10.1136/bmj.331.7527.1219<space/></arg><arg name="ref"><space/>harv<space/></arg></template></listitem><listitem><template><target>cite journal</target><arg name="url">http://www.csiro.au/solutions/Alternatives-to-antibodies.html<space/></arg><arg name="title">Alternatives to Antibiotics Reduce Animal Disease</arg><arg name="journal"><space/>Commonwealth Scientific and Industrial Research Organization</arg><arg name="date">9 Jan 2006</arg><arg name="ref">harv</arg></template></listitem></list><heading level='2'>External links</heading><list type='bullet'><listitem><link type='external' href='http://pharmaxchange.info/press/2011/02/animation-of-antimicrobial-resistance/'>Animation of Antibiotic Resistance</link></listitem><listitem><link type='external' href='http://www.cdc.gov/ncidod/dhqp/ar_mrsa_spotlight_2006.html'>CDC Article on Hospital Acquired MRSA</link></listitem><listitem><link type='external' href='http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html'>CDC Article on Community Acquired MRSA</link></listitem><listitem><link type='external' href='http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf'>CDC Guideline &quot;Management of Multidrug-Resistant Organisms in Healthcare Settings, 2006&quot;</link></listitem><listitem><link type='external' href='http://www.reactgroup.org/'>ReAct Action on Antibiotic Resistance</link></listitem><listitem><link type='external' href='http://www.apua.org/'>Alliance for the Prudent Use of Antibiotics</link></listitem><listitem><link type='external' href='http://www.eu-burden.info/burden/pages/home.php'>BURDEN of Resistance and Disease in European Nations An EU-Project to estimate the financial burden of antibiotic resistance in European Hospitals<space/></link></listitem><listitem><link type='external' href='http://www.extendingthecure.org/'>Extending the Cure: Policy Research to Extend Antibiotic Effectiveness<space/></link></listitem><listitem><link type='external' href='https://web.archive.org/web/20071214142631/http://www.fda.gov/oc/antimicrobial/questions.html'>2003 New Guidance for Industry on Antimicrobial Drugs for Food Animals Questions and Answers, U.S. FDA</link></listitem><listitem><link type='external' href='http://www.scidev.net/en/health/antibiotic-resistance/'>SciDev.net Antibiotic Resistance spotlight</link><space/>The<space/><link><target>Science and Development Network</target></link><space/>is an online science and development network focused on news and information important to the developing world</listitem><listitem><link type='external' href='http://www.dobugsneeddrugs.org/'>Do Bugs Need Drugs?</link></listitem><listitem><link type='external' href='http://www.pharmaceutical-int.com/article/combating-drug-resistance.html'>Combating Drug Resistance</link><space/>Tackling drug resistance in bacteria and other pathogens.</listitem><listitem><link type='external' href='http://www.technologyreview.com/news/513461/nanoparticle-disguised-as-a-blood-cell-fights-bacterial-infection/?utm_campaign=newsletters&amp;amp;utm_source=newsletter-daily-all&amp;amp;utm_medium=email&amp;amp;utm_content=20130415'>Nanoparticle Disguised as a Blood Cell Fights Bacterial Infection</link>,<space/><italics><link><target>MIT Technology Review</target></link></italics></listitem><listitem><link type='external' href='http://purl.fdlp.gov/GPO/gpo52306'>Report to the President on Combating Antibiotic Resistance</link><space/><link><target>Presidents Council of Advisors on Science and Technology</target></link></listitem><listitem><link type='external' href='http://resistancemap.cddep.org/'>Resistance Map</link><space/><link><target>Center for Disease Dynamics, Economics &amp; Policy</target></link></listitem></list><paragraph><template><target>Antibiotics social and layman issues</target></template><template><target>Pharmacology</target></template><template><target>Portal bar</target><arg>Molecular and Cellular Biology</arg><arg>Biology</arg><arg>Medicine</arg></template></paragraph><paragraph><template><target>DEFAULTSORT:Antibiotic Resistance</target></template><link><target>Category:Antibiotic resistance</target><part></part></link><link><target>Category:Antibiotics</target></link><link><target>Category:Evolutionary biology</target></link><link><target>Category:Health disasters</target></link><link><target>Category:Pharmaceuticals policy</target></link><link><target>Category:Veterinary medicine</target></link></paragraph></article>